Targeting immunosuppressive myeloid cells using nanocarriers to improve cancer immunotherapy by Sasso, Maria Stella
1 
 
 
 
 
 
UNIVERSITÀ DEGLI STUDI DI PADOVA 
 
DIPARTIMENTO DI SCIENZE CHIRURGICHE ONCOLOGICHE E 
GASTROENTEROLOGICHE 
___________________________________________________________________ 
Scuola di Dottorato di Ricerca in 
 Oncologia e Oncologia Chirurgica 
CICLO XXVII 
 
 
Targeting immunosuppressive myeloid 
cells using nanocarriers to improve cancer 
immunotherapy 
 
 
 
 
 
 
 
Direttore della Scuola: Ch.ma Prof.ssa Paola Zanovello 
Supervisore: Ch.mo Prof. Vincenzo Bronte  
                            Ch.ma  Dr.ssa Susanna Mandruzzato 
 
Dottoranda: Maria Stella Sasso 
2 
 
 
 
  
3 
 
Table of Contents 
 
Summary .......................................................................................................................................... 5 
Riassunto .......................................................................................................................................... 7 
Introduction ..................................................................................................................................... 9 
1. Myeloid-derived suppressor cells (MDSCs) ............................................................................ 10 
2. Tumor associated macrophages (TAMs) ................................................................................ 13 
3. Current approaches for cancer immunotherapy.................................................................... 17 
3.1. Immune check point inhibitors and cancer vaccines ....................................................... 17 
3.2.  Adoptive T cell therapy (ACT) ......................................................................................... 18 
4. Use of drug and RNA delivery nanosystems in oncology ....................................................... 22 
4.1.  Passive targeting of the tumor site: the EPR effect ........................................................ 22 
4.2.  Mechanisms of  immune recognition of nanocarriers .................................................... 24 
4.3.  Passive versus active tumor targeting ............................................................................ 26 
4.4.  Challenges in therapeutic RNA delivery .......................................................................... 27 
5. Targeting immunosuppressive and tumor-promoting myeloid cells using nanocarriers ...... 30 
5.1.  Targeting monocytes and  neutrophils ........................................................................... 31 
5.2.  Targeting MDSCs ............................................................................................................ 33 
5.3.  Targeting TAMs .............................................................................................................. 35 
Aim ................................................................................................................................................. 37 
Results ............................................................................................................................................ 39 
Biodistribution, pharmacokinetic, and cell uptake of lipid nanocapsules (LNCs) ...................... 39 
GemC12-loaded LNCs selectively deplete monocytic MDSCs and show improved efficacy over 
gemcitabine hydrochloride ........................................................................................................ 45 
Preconditioning with low dose LNC-GemC12 improves mouse survival following adoptive T cell 
therapy ....................................................................................................................................... 52 
Development of a nanosystem suitable for gene silencing in myeloid cells consisting in 
polyarginine nanocapsules loaded with fluorinated shRNAs ..................................................... 56 
The shRNA-loaded polyarginine nanocapsules down-regulate C/EBPβ expression in myeloid 
cells in vitro and in vivo .............................................................................................................. 58 
Discussion ....................................................................................................................................... 63 
Materials and methods ........................................................................................................ 73 
Mice ............................................................................................................................................ 73 
Cell lines ...................................................................................................................................... 73 
4 
 
Nanocarriers............................................................................................................................... 73 
Preparation of cell suspensions from tumors and lymphoid organs ......................................... 74 
Cytofluorimetric analysis ........................................................................................................... 74 
Ex vivo T cell suppression assay ................................................................................................. 74 
Fluorescent immunohistochemistry (IHC) ................................................................................. 75 
MDSCs generation from bone marrow cells .............................................................................. 75 
In vivo treatments on tumor bearing mice ................................................................................ 76 
Adoptive  T cell therapy (ACT) ................................................................................................... 76 
Pharmacokinetic and biodistribution of DiD-loaded LNCs (DiD-LNCs) in healthy mice ............. 76 
Cell transfection ......................................................................................................................... 77 
RNA extraction and qRT-PCR ..................................................................................................... 77 
Synthesis of fluorinated short hairpin (sh) RNAs ....................................................................... 78 
Statistical analysis ...................................................................................................................... 78 
Abbreviations ................................................................................................................................ 79 
References ..................................................................................................................................... 83 
Acknowledgments ......................................................................................................................... 93 
Appendix ........................................................................................................................................ 95 
Scientific publications ................................................................................................................ 95 
Attended meetings and conferences with written or oral presentation................................... 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Summary 
 
In the last decade, different cancer immunotherapy approaches have been proved to produce 
objective clinical responses and survival benefits in cancer patients who failed conventional 
treatment options. However, the efficacy of cancer immunotherapy is known to be limited by 
tumor-induced expansion of immunosuppressive and tumor-promoting immune populations, 
including cells of myeloid origin (such as tumor associated macrophages –TAMs-, and myeloid-
derived suppressor cells –MDSCs-). The development of increasingly powerful and widely 
applicable immunotherapies is therefore dependent on the availability of supporting treatments 
able to reduce tumor-associated immunosuppression, with good efficacy and low toxicity.  Drug 
delivery nanosystems have been shown to improve pharmacological proprieties of anti-cancer 
drugs by increasing drug half-life, enhancing accumulation into tumor tissues and reducing off-
target toxicity. In addition, the use of RNA delivery nanosystems is currently being explored for 
the development of RNA intereference (RNAi)-based anti-cancer therapeutics. The use of drug 
and RNA delivery nanosystems to target tumor-associated immune cells, besides tumor cells, is a 
far less explored approach, which is currently showing promise as tool to improve cancer 
immunotherapy.  
In the present work we investigated two different nanotechnology-based tools to modulate the 
presence and function of tumor-associated myeloid cells: a modified form of gemcitabine 
encapsulated into lipid nanocapsules (LNC-GemC12), and ployarginine-coated nanocapsules 
(PolyArg NCs) loaded with short hairpin (sh) RNAs, for in vivo RNAi-based gene silencing. 
LNC-GemC12 and free gemcitabine hydrochloride (GemHCl, the current standard gemcitabine 
formulation) were found to selectively deplete both splenic and tumor-infiltrating monocytic  
(M-) MDSCs, following administration at a very low drug dose to EG7-OVA tumor bearing mice.  
Remarkably, LNC-GemC12 administration was associated with a stronger and more durable 
reduction of tumor-infiltrating M-MDSCs as compared with GemHCl, which resulted in the 
attenuation of MDSC suppressive activity towards T cells.  More importantly, treatment of EG7-
OVA tumor bearing mice with LNC-GemC12, prior to adoptive cell transfer therapy (ACT) with 
OVA-specific T lymphocytes, significantly extended mouse survival as compared to mice 
receiving ACT alone. Conversely, preconditioning with GemHCl at the same dose did not result in 
a similar survival benefit. 
PolyArg NCs were loaded with a fluorinated shRNA specific for mouse C/EBPβ transcription 
factor, which is known to be required for tumor-induced MDSC expansion and acquisition of 
immunosuppressive functions. PolyArg NCs loaded with the C/EBPβ-specific shRNA (NC-
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shC/EBPβ) efficiently down-regulated target gene expression in an immortalized MDSC cell line. 
In vivo, we reported a significant reduction of C/EBPβ mRNA levels in splenic and tumor-
infiltrating myeloid cells, following repeated administration of NC-shC/EBPβ to mice bearing 
MCA203 subcutaneous sarcomas.  
The present data support the use of LNC-GemC12 as MDSC-targeted agent in cancer 
immunotherapy, notably in combination with ACT.  As compared with standard MDSC-depleting 
chemotherapeutic drug formulations, LNC-GemC12 bears the potential of achieving significant 
effects at very low, likely not toxic, drug doses. Moreover, the use of a drug already employed in 
clinical oncology, combined with a biocompatible delivery nanosystem, might facilitate clinical 
translation. We also provided an initial evidence that shRNA-loaded PolyArg NCs allow to 
downregulate target gene expression in myeloid cells in vivo, and could be exploited to 
therapeutically  modulate tumor-associated myeloid cells. 
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Riassunto 
 
Nell’ultimo decennio l’impiego di diversi tipi di immunoterapia dei tumori ha consentito di 
ottenere  risposte cliniche e un miglioramento della sopravvivenza in pazienti non rispondenti 
alle terapie convenzionali. Tuttavia, l’efficacia dell’immunoterapia del cancro è limitata dalla 
presenza di popolazioni di cellule immunitarie con proprietà immunosoppressive e pro-tumorali 
che si espandono durante la patogenesi della malattia. Tali cellule comprendono popolazioni di 
origine mieloide, quali i macrofagi associati al tumore (tumor associated macrophages, TAMs), e 
cellule soppressive di derivazione mieloide (myeloid derived suppressor cells, MDSCs). Pertanto, 
per lo sviluppo di protocolli d’immunoterapia ottimali sono necessari trattamenti di supporto,  
con buona efficacia e bassa tossicità, in grado di contrastare l’immunosoppressione indotta dal 
tumore. Diversi studi preclinici e clinici hanno dimostrato che i nanosistemi per il trasporto di 
farmaci antitumorali sono in grado di migliorarne le proprietà farmacologiche aumentandone 
l’emivita, favorendone l’accumulo nel sito tumorale e limitando la tossicità a carico di tessuti 
sani. Inoltre, i nanosistemi per il trasporto di RNA sono  attualmente impiegati nello sviluppo di 
terapie antineoplastiche che utilizzano approcci di silenziamento genico in vivo basati sul 
meccanismo dell’Interferenza a RNA (RNAi). L’uso di nanosistemi per il trasporto di farmaci ed 
RNA che hanno come target le cellule sistema immunitario, oltre alle cellule tumorali, sembra 
essere un nuovo e promettente approccio per potenziare l’efficienza dell’immunoterapia dei 
tumori. 
In questo lavoro abbiamo valutato l’efficacia di due diverse formulazioni di nanotrasportatori, 
caricati con farmaci o RNA, come agenti immunomodulanti per alterare la presenza e/o funzione 
delle cellule mieloidi associate al tumore. La prima formulazione consiste in una forma 
modificata di gemcitabina incapsulata in nanocapsule lipidiche (LNC-GemC12); la seconda è 
costituita da nanocapsule rivestite di poliarginina (PolyArg NCs) caricate con short hairpin (sh) 
RNA, per il silenziamento genico in vivo mediante RNAi. 
Nel modello tumorale murino EG7-OVA, la somministrazione di LNC-GemC12 e di gemcitabina 
idrocloruro (GemHCl, l’attuale formulazione standard per la gemcitabina), ad un dosaggio molto 
basso, causa una deplezione selettiva delle MDSC monocitarie (M-MDSCs) nella milza e nel sito 
tumorale. In particolare, alla somministrazione di LNC-GemC12, rispetto alla GemHCl, si associa 
una riduzione più intensa e prolungata delle M-MDSCs tumorali ed una conseguente 
attenuazione dell’attività soppressiva delle MDSC infiltranti il tumore nei confronti dei linfociti T. 
Inoltre, nello stesso modello, il trattamento con LNC-GemC12 prima della somministrazione di 
una terapia di trasferimento cellulare adottivo (ACT) con linfociti T OVA-specifici, risulta in un 
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miglioramento della sopravvivenza rispetto al solo trattamento mediante ACT. In confronto, il 
pre-trattamento con GemHCl alla stessa dose non si associa ad un’estensione della 
sopravvivenza dopo ACT. 
Nella seconda parte di questo lavoro, le PolyArg NC sono state caricate con un shRNA fluorinato 
specifico per il fattore di trascrizione murino C/EBPβ, la cui espressione è necessaria per 
l’espansione e l’induzione di funzioni immunosoppressive nelle MDSC. Le PolyArg NC caricate 
con l’shRNA C/EBPβ-specifico (NC-shC/EBPβ) sono state impiegate con successo per ridurre 
l’espressione del gene bersaglio in una linea cellulare di MDSC immortalizzate. Successivamente, 
abbiamo valutato il funzionamento di questo sistema in vivo in un modello murino di sarcoma 
sottocutaneo. In questo modello abbiamo riportato una riduzione significativa nei livelli di mRNA 
di C/EBPβ nelle cellule mieloidi spleniche e intratumorali a seguito della somministrazione 
ripetuta di NC-shC/EBPβ. 
I dati ottenuti in questo lavoro supportano la validità dell’uso delle LNC-GemC12 come agente 
per la modulazione delle MDSC nell’immunoterapia del cancro, in particolare in combinazione 
con l’ACT. Rispetto alle formulazioni standard di agenti chemioterapici in grado di ridurre la 
frequenza delle MDSC, le LNC-GemC12 hanno il potenziale di fornire un’efficacia terapeutica a 
dosaggi di farmaco molto bassi e verosimilmente non tossici. In aggiunta, l’utilizzo di un farmaco 
già in uso nella pratica clinica, combinato con una formulazione di nano capsule lipidiche 
biocompatibili, potrebbe facilitare la traslazione in ambito clinico di questo approccio. Nel 
presente studio, abbiamo inoltre fornito una prima validazione dell’efficacia in vivo delle PolyArg 
NC caricate con shRNA come strumento per ridurre l’espressione di geni bersaglio nelle cellule 
mieloidi associate al tumore, potenzialmente impiegabile come agente immunomodulante nella 
terapia del cancro. 
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Introduction 
 
The interaction between immune cells and tumor cells is currently recognized to play a critical 
role in cancer pathogenesis1. In cancer, the immune system acts like a double-edged sword, 
since it includes both components able to detect and destroy tumor cells (as cytotoxic T cells and 
Natural Killer cells) and cells that suppress this anti-tumor response and/or directly support 
tumor proliferation, invasion and metastasis2. With the substantial progresses made in the last 
20 years in the field of cancer immunotherapy (i.e. harnessing the immune system to destroy 
tumors), a growing consideration has been given to the concept that the immunosuppressive 
cell subsets, which support cancer pathogenesis, are also a major obstacle to the efficacy of 
immunotherapeutic approaches 3. Based on this concept, along with the development of 
increasingly refined and effective strategies to directly potentiate the immune-mediated 
cytotoxicity (e.g. by the generation of highly potent and versatile engineered T cytotoxic cells4) 
also new approaches to specifically eliminate or modulate tumor-associated immunosuppressive 
and tumor promoting cells have been investigated.  The combination of these complementary 
strategies is ultimately expected to maximize the efficacy of cancer immunotherapy.  
Immune populations known to support cancer progression by different mechanisms include T 
regulatory cells (Tregs) and cells of myeloid origin, such as tumor associated macrophages 
(TAMs), myeloid-derived suppressor cells (MDSCs), and dendritic cells (DCs). Tregs are a peculiar 
population of T lymphocytes endowed with immunosuppressive functions. Tumor-infiltrating 
Tregs may be either natural occurring T regs, generated during thymic development and 
recruited in the tumor site by tumor-derived chemokines5,6  and induced Tregs that differentiate 
in situ from CD4+ T lymphocytes under the influence of microenvironmental stimuli7. DCs are 
strictly required to mount an adaptive immune response against tumor cells, since these cells 
are highly specialized antigen presenting cells, with the unique ability to activate naïve T 
lymphocytes8. However, in cancer DCs are often prone to bear an immature and dysfunctional 
state, characterized by low costimulatory molecule expression and poor activating abilities9. 
Moreover these cells may also exert an active immunosuppressive function, mainly relying on 
the expression of the enzyme indoleamine 2,3-dioxygenase (IDO). IDO expression by DCs results 
in the microenvironnemental depletion of  L-Tryptophan, and in the accumulation of its 
catabolites, which  both inhibit T cell activation and function10. 
Among populations of myeloid origin, MDSCs and TAMs exert the strongest immunosuppressive 
and tumor-promoting functions. These two populations are extensively described below. The 
following paragraphs will also provide an overview of cancer immunotherapy approaches, which 
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have so far achieved the best results in clinical evaluations, and of current successes and 
challenges in the use of delivery nanosystems in oncology. Last paragraphs will be dedicated to 
the application of delivery nanosystems in cancer immunotherapy and notably in the 
modulation of tumor-promoting and immunosuppressive cell populations. 
 
1. Myeloid-derived suppressor cells (MDSCs) 
 
Myeloid-derived suppressor cells (MDSCs) are an immune population of myeloid origin 
characterized by a strong immunosuppressive activity and heterogeneous composition, including 
monocytic and granulocytic cells, and more immature precursor cells. In mice, MDSCs were 
originally identified as CD11b+Gr1+ cells that expanded during cancer growth, accumulating both 
within the tumor site and in peripheral lymphoid organs, notably in the spleen11. The initial 
identification and most information on MDSCs derive from studies in tumor models; however, 
their expansion has been reported also under other pathological conditions, including  parasitic 
infection12-14 polymicrobial sepsi 15, autoimmunity16, inflammatory bowel disease17 and trauma18. 
Currently, the monocytic and granulocytic fraction of mouse MDSCs are commonly distinguished 
on the basis of the differential expression of Ly6C and Ly6G markers (two protein isoforms 
recognized by anti-Gr1 antibody): monocitic (M-)MDSCs have a CD11b+Ly6G-Ly6Chighphenotype, 
while polymorphonuclear/granulocytic (PMN-)MDSCs are CD11b+Ly6G+Ly6Cint/low 19. 
Alternatively, M- and PMN-MDSCs have been discriminated based on the intensity of Gr1 
marker, since CD11b+Gr1high cells substantially correspond to Ly6G+Ly6Cint/low PMN-MDSCs, while 
the CD11B+Gr1int/low fraction include M-MDSCs20,21. M-MDSCs also express common markers of 
inflammatory monocytes as F4/80, CD115, and CCR220-22. Indeed, M-MDSC phenotypically 
resemble mouse Ly6Chigh inflammatory monocytes10, and are likely to represent, at least in part, 
a peculiar cancer-induced functional state of monocytes, with the fundamental distinction that 
inflammatory monocytes do not bear immunosuppressive functions. Similarly, PMN-MDSCs 
phenotipically resemble normal granulocytes, except for the increased expression of markers 
that are poorly expressed by granulocytes, such as CD244 and CD115 23. For these reasons, the 
unambiguous definition of the MDSC populations requires assessment of immunosuppressive 
functions by ex-vivo or in vivo assays, and other functional evaluations. For instance, mouse 
PMN-MDSCs have been reported to have lower phagocytic ability, lower Tumor Necrosis Factor 
(TNF)α expression and higher ARG1 and myeloperoxidase expression and ROS production as 
compared with neutrophils23. Likewise, the expression of proteins related to MDSC suppressive 
activity, as ARG1 and inducible Nitric Oxide synthase (iNOS, see below), may allow to identify 
11 
 
better M-MDSCs. Of note, MDSCs isolated from the spleen of tumor-bearing mice have been 
reported to include cells with morphologic, phenotypic and functional features of myeloid 
precursor cells, which are not found in the spleen of healthy mice21,24,25. Indeed, the spleen is a 
unique site of cancer-associated extramedullary hematopoiesis in mice, and there is evidence 
that splenic hematopoiesis might occur also in cancer patients26. 
Like mouse MDSCs, human MDSCs comprise monocytic and granulocytic subsets, although for 
each subset multiple phenotypes have been reported, accounting for the higher heterogeneity 
and complexity in human MDSC definition as compared to mouse MDSCs27.  Most commonly 
reported fenotypes are CD14+IL4Rα+, CD14+/HLA-DRlow/- and CD15-/CD14+/CD33high/HLA-DRlow/- 
for human M-MDSCs;  CD15+IL4Rα+, CD14-/CD15+/CD11b+ and CD15high/FSClow/SSChigh for PMN-
MDSCs19. In addition, human MDSCs include a more immature subset, which is not stained by 
lineage marker cocktails and expresses the common myeloid markers CD33 and CD11b (Lin-
/HLA-DR- /CD33+/CD11b+ phenotype)19. 
MDSC expansion in peripheral blood of cancer patients or, less often, in tumor clinical 
specimens, has been described in multiple cancer types27. Remarkably, various studies on 
different human solid tumors reported the existence of a positive correlation between higher 
circulating MDSC frequency or absolute numbers and clinical parameters as increasingly 
advanced cancer stages, greater metastatic burden, and worse patient prognosis28-31. In the 
same studies, MDSC ability to suppress T cell proliferation and IFNγ secretion was assessed by ex 
vivo assays, thus confirming the immunosuppressive nature of these cells. 
Different tumor-derived factors, including prostaglandins, granulocyte-macrophage colony 
stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony 
stimulating factor (M-CSF), stem cell factor (SCF), and vascular endothelial growth factor (VEGF) 
have been shown to promote MDSC expansion, mostly identified in mouse tumor models11. Pro-
inflammatory mediators released by both tumor cells and tumor-activated infiltrating immune 
cells, as interleukin-1β (IL-1β), IL-6, IL-4, IL-10, IL-13, S100 calcium binding protein A8 and A9 
(S100A8 and S100A9), interferon gamma (IFN-γ), induce the activation of immunosuppressive 
and tumor-promoting functions in myeloid cells11. 
The above reported signals are known to activate different transcription factors, which regulate 
MDSC expansion, survival and suppressive programs. Among these factors a major role is played 
by proteins of the signal transducer and activator of transcription family (STAT), notably STAT3, 
STAT1 and STAT6, and by nuclear factor κB (NF‑κB) and CCAAT/enhancer-binding protein-β 
(C/EBPβ)10. 
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MDSCs exploit different mechanisms to inhibit T cell recruitment, activation and proliferation, 
which have been extensively investigated in mouse tumor models. One of the first described 
mechanisms is the upregulation of the L-arginine metabolizing enzyme ARG1. T cell proliferation 
is possibly inhibited by the activation of intracellular regulatory pathways, which sense amino 
acid starvation and accumulation of catabolytes and repress protein synthesis32. Notably, L-
arginine depletion from the tumor microenvironment impairs T cell activation by blocking the re-
expression of the CD3 ζ chain of the TCR complex after antigen stimulation33. In addition, MDSC 
cell metabolism results in the local depletion of extracellular cysteine, which is also required for 
T cell activation and function34. 
Another known mechanism of MDSC-mediated immune suppression is the release of reactive 
oxygen and nitrogen species (ROS/RNS). Nitric oxide (NO) production by iNOS, upregulated in 
MDSCs, results in the block of signaling pathways downstream of the IL-2 receptor, thus 
impairing T cell activation and proliferation35. Human peripheral blood mononuclear cells 
(PBMCs) exposure to NO reduces IL-2 expression and release, thus impairing T cell 
proliferation36. 
The simultaneous activity of ARG1 and iNOS has been shown to exert a synergistic 
immunosuppressive function, by resulting in an enhanced production of superoxide anion 02
- by 
the iNOS reductase domain37. L-arginine substrate consumption by ARG1 is thought to shift iNOS 
enzymatic activity from NO production to superoxide anion (O2
-) production, due to the reduced 
concentration of the amino acid substrate; the superoxide anion in turn reacts with NO to 
produce peroxinitrite (ONOO–), a potent nitrating agent32,38. MDSC-derived peroxinitrite was 
shown to impair antigen recognition of CD8+ T cells by nitrating T cell receptor (TCR) and CD8 
molecules on their surface, and in this way preventing the proper binding to major 
histocompatibility complexes (MHC) loaded with antigenic peptides39. Moreover, peroxinitrite 
nitrates the CC-chemokine ligand 2 (CCL2) released within the tumor microenvironment, thus 
inhibiting T cell recruitment mediated by this chemokine40. 
In addition, in mouse tumor models MDSC-mediated immune suppression was shown to depend 
on the production of reactive oxygen species (ROS), mainly including H2O2
41. Consistently, the 
presence of circulating, activated granulocytes in cancer patients was found to correlate with 
reduced T-cell receptor ζ chain expression and decreased cytokine production by T cells, and 
granulocyte-mediated immunosuppression appeared to be mainly due to H2O2 production
42. 
In works considering separately M-MDSC and PMN-MDSC immunosuppressive activity, M-
MDSC-mediated suppression was found to be more dependent on NO release, while PMN-
MDSCs produced greater amounts of ROS and lower amount of NO as compared with M-
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MDSC20,43. In addition, although PMN-MDSCs generally represent a more abundant population in 
spleens of tumor bearing mice, M-MDSCs exerted a stronger immune suppressive activity on a 
per-cell basis20,22,25,44. 
Besides restraining cell function, MDSCs have also reported to inhibit Natural killer (NK) cells45-47  
and to promote the differentiation and expansion of Tregs. Notably, Gr1+CD115+MDSCs, likely 
corresponding to the monocytic subset, were found to induce the in vivo expansion of Tregs by 
mechanisms involving both soluble factors (IFNγ, IL-10) and expression of the CD40 receptor 
48,49. In addition, M-MDSCs were reported to recruit Tregs in tumors by secreting CCR5-binding 
chemokines50. 
Recently, a new potential mechanism of tumor promotion by MDSCs has been discovered, since 
CD11b+Gr1+cells (possibly corresponding to MDSCs) were found to strongly infiltrate benign 
prostate tumors and favor the evasion of tumor cell senescence, thus promoting the progression 
to malignancy51. 
In addition to direct immunosuppressive and pro-tumor functions, MDSCs also contribute to 
replenish the tumor-associated macrophage (TAM) pool. MDSC recruited into the tumor site 
have the ability to differentiate in pro-tumoral TAMs under microenvironment stimuli as 
hypoxia, a property that is likely due to the M-MDSC component, since monocytes are natural 
macrophage precursors52. Consistently, selective depletion of monocytes in blood and lymphoid 
organs, including splenic immunosuppressive M-MDSCs, by the chemotherapeutic drug 
trabectedin resulted in TAM reduction in multiple mouse cancer models53. Other studies 
demonstrating TAM differentiation from Ly6C+ monocytes54,55  further support M-MDSC 
contribution to the generation of TAMs, since the monocytic phenotype may indeed identify 
immunosuppressive M-MDSCs in cancer model, as discussed above.  
 
2. Tumor associated macrophages (TAMs) 
 
In mice, TAMs primarily descend from circulating inflammatory monocytes and M-MDSCs and 
are maintained by both monocyte recruitment and differentiation, and in situ TAM proliferation 
54,55. However, it is worth to note that macrophage populations found in peripheral tissues, in 
healthy and disease, are extremely heterogeneous. Moreover, tissue-resident macrophage 
populations descending from primitive yolk-sack-derived macrophages or from fetal liver 
monocytes, rather than from blood monocytes, have recently been identified56-58. These resident 
macrophages are maintained by self-renewing during the adult life, without being replenished 
by the circulating monocyte pool.  
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Mouse macrophages are phenotypically identified based on the expression of CD11b, F4/80 and 
CD115 (colony stimulating factor 1 receptor, CSF-1R) markers and absence of expression of Ly6G 
marker, while in humans macrophages express CD68, CD163, CD16, CD312 and CD115 
antigens59. However, in mice TAMs may also express classical DC markers such as MHCII and 
CD11c54, thus rendering difficult the unambiguous definition of this population only based on 
their phenotypic characterization. Functional assays and gene expression profiling can provide 
additional tools to better define TAM populations54. 
TAMs have been reported to bear an alternative functional polarization, termed “M2”, in 
opposition to the classical pro-inflammatory activation status, or “M1”. The M1 and M2 states 
are induced by different environmental factors, including cytokines and toll-like receptor ligands, 
and are characterized by specific functional properties. M1 macrophages are efficient antigen-
presenting cells, have an high production of reactive oxygen and nitrogen species, exert a strong 
cytotoxic activity against pathogens and tumor cells, express high levels of pro-inflammatory 
cytokines, and promote a “Th1-oriented” T cell response. Conversely, M2 macrophages have 
poor antigen presenting abilities, express high level of mannose, scavenger and galactose-type 
receptors, produce low amounts of pro-inflammatory cytokines and high levels of the anti-
inflammatory cytokine IL-10, and are typically involved in the resolution of inflammation and 
tissue remodeling60. However, the dichotomic M1/M2 distinction is oversimplified, since cells 
may bear intermediate phenotypes and functions 61. In addition, although TAMs are generally 
thought to bear an M2-like phenotype, at least in advanced tumors, the M2 phenotypic 
signature does not always characterize TAMs in experimental cancer models54. 
Beyond the M1-M2 phenotypic distinction, which is not always straightforward, TAMs have been 
generally reported to play a strong pro-tumor role. Different pro-tumor functions have been 
described for TAMs, including suppression of anti-tumor immunity, promotion of cancer cell 
growth, angiogenesis and metastasis (Fig. 1). Consistently, TAMs are an independent negative 
prognostic factor in human cancers62,63.  
Tumor-associated monocytes/macrophages upregulate the membrane molecule programmed 
death ligand 1 (PD-L1), which binds to the inhibitory receptor PD1 on T cell membrane, thus 
restraining T cell proliferation and function64,65. In a recent work, PD-L1 was reported to be 
upregulated in tumor-infiltrating MDSCs and macrophages upon exposure to hypoxia, via 
hypoxia inducible factor-1α (HIF-1α) activation66. In addition, TAMs may express the non-
classical HLA molecules HLA-G and HLA-E, in membrane-bound or soluble form, which binds 
inhibitory receptors on NK cells67. 
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TAMs have been reported to secrete Treg-attracting chemockines, including CCL225, CCL206 and 
CCL568,69. TGF-β and IL-10 released by TAMs may contribute to the local induction of Tregs 
differentiation from CD4+ T cells and also exert an inhibitory activity on T cytotoxic and helper 
cells70. Mouse TAMs, as MDSCs, express the enzyme ARG133,71, which locally depletes L-arginine, 
thus impairing T cell activation and proliferation, as discussed above.  
Besides contributing to tumor-associated immunosuppression, TAMs are known to directly 
support critical steps of cancer pathogenesis. First, TAMs participate in tumor-induced neo-
angiogenesis, which is required for continuous tumor growth and progression to malignancy1. 
One of the main mechanisms of angiogenesis promotion is macrophage-dependent VEGF 
release 72,73. Notably, TAMs have been recently reported to induce VEGF secretion by endothelial 
cells through the release of the WNT family ligand WNT7B74. Pro-angiogenic myeloid cells are 
characterized by the expression of the Angiopoietin2 (ANG2) receptor TIE2 75.  Tie2+ 
macrophages interact with ANG2 expressing endothelial cells and this signalling pathway results 
in macrophage association with blood vessels and pro-angiogenic function76. 
TAMs express high level of different proteases, which support tumor cell mobility and invasion 
through the degradation and remodeling of the extracellular matrix77. In addition, macrophages 
directly stimulate tumor cell migration through the secretion of paracrine factors.  In the PyMT 
breast cancer model, Wyckoff et coworkers described a paracrine signalling loop consisting in 
the stimulation of tumor cell motility by TAM-derived EGF and induction of TAM migration by 
tumor-derived CSF-1, resulting in the coordinated migration of both cell types78. A different 
TAM-derived molecule, protein acidic and rich in cysteine (SPARC), also known as osteonectin, 
was reported to favor cancer cell migration by promoting the interaction between cancer cells 
and the extracellular matrix79. In addition perivascular TAMs were shown to directly interact 
with cancer cells and favor their ingress into blood vessels80. 
The combination of pro-angiogenic functions and promotion of cancer cell motility and ingress 
into blood vessels collectively results in a strong promotion of tumor spread by TAMs. However, 
the mechanisms underlining the process of distant metastasis formation by circulating tumor 
cells are still incompletely understood. Myeloid cells are known to play a critical role in this 
process. Tumor-derived soluble factors, released systemically, can induce the accumulation of 
myeloid cells at distant sites, thus increasing the efficiency of metastatic cell seeding at those 
sites, defined pre-metastatic niches. In metastatic lung cancer and melanoma mouse models, 
the secretion of S100A8 and S100A9 inflammatory mediators in lungs, released in response to 
soluble factors produced by the primary tumor, was found to mediate myeloid cell recruitment 
into pre-metastatic sites81. In the same models, tumor-induced upregulation of fibronectin in 
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pre-metastatic lungs was reported to mediate the adhesion of circulating VEGFR1+ 
hematopoietic progenitors expressing the VLA-4 integrin, which were in turn required to support 
tumor cell seeding82. Studies on lung metastasis formation have shown that cancer cells can 
express pro-coagulant molecules, as the tissue factor, which promote the formation of clots 
containing platelets and tumor cells in lung vessels 83. Clotting, in turn, favors the recruitment of 
myeloid cells at the pre-metastatic site 83,84 by a mechanism involving endothelium activation 
and expression of the adhesion molecules vascular cell adhesion molecule-1 (VCAM-1) and 
vascular adhesion protein-1 (VAP-1) 84. Circulating myeloid cells recruited at pre-metastatic sites 
may then differentiate into metastasis-associated macrophages, which increase the efficiency of 
circulating tumor cell extravasation and promote the subsequent growth of metastatic 
lesions70,85. 
 
 
 
Figure 1. Tumor-promoting functions of TAMs. TAMs sustain tumor cell growth, and promote 
tumor spread by mediating matrix remodeling and supporting tumor cell motility and ingress into 
blood vessels. TAMs also promote angiogenesis, which is required for continuous growth of the 
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primary tumor ad favor tumor cell ingress into blood circulation. In addition, TAMs support tumor 
cell seeding and proliferation at the pre-metastatic niche and mediate tumor-induced 
immunosuppression by multiple mechanisms.  
Adapted from: P.Allavena and A.Mantovani. Clinical and Experimental immunology 2012. 
 
3. Current approaches for cancer immunotherapy 
 
Cancer immunotherapy exploits immune-mediated cytotoxicity (primarily dependent on CD8+ T 
cells) to fight tumors. To date, different approaches have been developed to potentiate the 
immune response against tumor cells, evaluated at clinical and preclinical levels. Approaches 
that have been studied in clinical trials, and that in some cases leaded to FDA drug approval, 
include inhibitors of immune checkpoints, cancer vaccines and the adoptive transfer of tumor-
specific T cells. 
 
3.1. Immune check point inhibitors and cancer vaccines 
 
Among immune checkpoint inhibitors, ipilimumab, a blocking antibody targeting the inhibitory 
molecule Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), was positively evaluated in a 
series of clinical trials and in 2011 the drug was finally approved by the FDA for the treatment of 
unresectable or metastatic melanoma86. Notably, in a paper dated 2010, ipilimumab was 
reported to improve the overall survival of patients with late-stage, metastatic melanoma that 
failed previous therapies, as compared with patients receiving a gp100 vaccine87. Ipilimumab 
therapeutic effect relies on the block of the immune checkpoint mediated by the CTLA-4 
molecules. CTLA-4 competes with the activating receptor CD28 for the binding to B7.1/B7.2 
costimulatory molecules on the surface of antigen presenting cells, thus preventing a proper T 
cell activation upon antigen recognition86. Blocking this checkpoint promotes a stronger and 
sustained T cell activation. In addition, the efficacy of anti-CTLA-4 antibodies may be in part also 
due to interference with Treg-mediated immunosuppression88. 
Currently, antibodies targeting programmed death-1 (PD-1) receptor, a different T cell and B cell 
negative regulator, or its ligand PD-L1, are in phase of clinical evaluation. A phase 1 clinical trial 
evaluating the antitumor activity and safety of a PD-1 blocking antibody (nivolumab) reported 
durable objective clinical responses in patients with non-small-cell lung cancer, melanoma, or 
renal–cell cancer89. Recently, the overall survival outcomes for advanced melanoma patients 
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treated with nivolumab were reported and considered positively as compared with previous 
clinical studies evaluating other treatments in the same population90. In addition, treatment of 
patients with advanced cancers with an antibody targeting PD-L1 was proven to induce durable 
tumor regression with an objective response rate of 6 to 17%, or prolonged stabilization of 
disease (12-41% of patients)91. 
Therapeutic cancer vaccines are designed to immunize patients against tumor-associated 
antigens in order to boost the endogenous immune response. Effective vaccination requires 
exposition of the immune system to a cancer antigen, which can be the product of a mutated 
cancer gene, the product of a non-mutated gene overexpressed by cancer cells, or a 
differentiation antigen associated with the histological cancer type. Antigens have to be 
associated with immunological adjuvants in order to induce DC maturation and proficient 
antigen presentation to lymphocytes, ultimately resulting in the induction of an antigen-specific 
immune response92. Various approaches for therapeutic cancer vaccination have been 
developed, including administration of antigenic peptides or full-length proteins together with 
adjuvant moieties, viral vectors encoding tumour antigens, vaccine based on full tumor cells and 
DC-based vaccines92. In this latter approach, DCs are isolated from a cancer patient, loaded with 
antigens ex vivo, activated and then re-infused back into the patient. However, most of these 
approaches showed modest or not significant benefits in clinical trials92. A single therapeutic 
cancer vaccine received FDA approval in 2010 for the treatment of advanced prostate cancer, 
marketed with the name of Provenge (sipuleucel-T). Sipuleucel-T was prepared by stimulation of 
isolated peripheral blood mononuclear cells with a fusion protein composed of prostatic acid 
phosphatase (a tumor-associated differentiation antigen) and GM-CSF, followed by the 
reinfusion of activated mononuclear cells into the patients. Such vaccination approach resulted 
in a 4.1 median survival improvement in prostate patients, considered meaningful due to the 
peculiarity of treated population, which has advanced disease with poor treatment options93. 
Another example of successful cancer vaccine is a peptide vaccine for melanoma, consisting in 
gp100 peptide administer together with incomplete Freund's adjuvant and IL-2 infusion, which 
resulted in an higher response rate and longer progression-free survival (2.2 months) in patients 
with advanced melanoma as compared with patients treated with IL-2 alone94. 
 
3.2.  Adoptive T cell therapy (ACT) 
 
Adoptive T cell therapy (ACT) consists in the infusion of in vitro generated cytotoxic lymphocytes 
(CTLs) with tumor antigen specificity. In first pivotal works on melanoma, CTLs were obtained by 
19 
 
ex-vivo selection and expansion of tumor-infiltrating lymphocytes isolated from patient tumor 
specimens. This approach gave considerable results in 3 sequential clinical trials on metastatic 
melanoma patients who failed previous treatment options. These trials reported objective 
response rates up to 72% and an overall 22% rate of complete tumor regression, which was in 
most cases durable beyond 3 years95. Of note, the efficacy of CTL transfer in melanoma patients 
was dependent on therapy combination with IL-2 administration, aimed at stimulating 
proliferation of transferred T cells, and preconditioning lympho-depleting or lympho-
depleting/myelo-ablating regimens. Myelo-ablating total body irradiation was followed by the 
infusion of autologous cryo-preserved CD34+ hematopoietic stem cells from a G-CSF-mobilized 
pheresis95. Combination of chemotherapy-based lympho-depletion (fludarabine plus 
cyclophosphamide) with total body irradiation was found to increase patient response to ACT as 
compared to chemotherapy alone95. Remarkably increased irradiation doses were found to 
correlate with improved immune response to ACT in cancer patients and mouse models95,96. 
Different mechanisms are thought to account for the positive impact of increasingly severe 
preconditioning regimens on ACT efficacy. First, the increased availability of homeostatic 
cytokines stimulating transferred T cell proliferation and function after depletion of competing 
endogenous lymphocytes. Other proposed mechanisms are the induction of tissue damage and 
consequent inflammation, which results in the maturation of antigen presenting cells (APCs), 
and the depletion of immunosuppressive cellular elements3. Notably, at least part of APC 
activation may be triggered by translocation of bacterial products into the blood following 
damage to the gut mucosal barrier97. Reduced immunosuppression following lympho/myelo-
ablating regimens is currently attributed to the elimination of both Tregs and 
immunosuppressive cells of myeloid origin3. Remarkably, in mouse tumor models ACT efficacy is 
improved by either targeted MDSC depletion with selected chemotherapeutic drugs, in absence 
of T lymphocyte frequency reduction 21, or attenuation of MDSC-dependent mechanisms of 
immunosuppression by pharmacological inhibition of ARG1 and iNOS40,98.  In addition, in 
conditional knock-out mice lacking the C/EBPβ transcription factor in the hematopoietic 
compartment,  MDSC are poorly expanded during tumor growth and bear poor 
immunosuppressive functions99. In these mice ACT approaches  show dramatically increased 
potency as compared to wild type mice. 
The major drawback of preconditioning treatments based on chemotherapy plus total body 
irradiation, currently employed in clinical setting, is the potential of severe toxicity that limits 
therapy extension to highly selected patients with a good performance status and normal organ 
function100,101. The development of more effective and widely applicable immunotherapies, 
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starting from ACT based approaches, is therefore dependent on the availability of supporting 
treatments aimed at reducing tumor-associated immunosuppression with good efficacy and low 
toxicity. The search for highly selective strategies to target and neutralize immunosuppressive 
cells may provide a great advantage in this respect. 
Even though ACT based on TIL isolation, ex vivo expansion and reinfusion into patients showed 
efficacy in different clinical trials on melanoma, translating this approach to other human 
cancers is challenging. Indeed, functional TILs  can rarely be isolated from human tumors other 
than melanoma3.  Such peculiarity is thought to arise from the lower mutational state and 
consequent immunogenicity of most cancer types compared to melanoma. If this is true, ACT 
approaches using TILs can be tailored only for a few other highly mutated cancers, as smoke-
related lung cancer3. In order to extend ACT applicability to most human tumors, approaches to 
generate transgenic cytotoxic T cells have been developed in the last years. Such approaches 
bypass the need of having a relatively strong, naturally occurring anti-tumor T cell response in 
each single patient, by providing the patients with artificially designed tumor-specific T cells.  A 
first strategy consists in the generation of T cells expressing chimeric antigen receptors (CARs) in 
which an antibody single-chain variable fragments is joined with TCR and T-cell costimulatory 
receptor domains, thus conferring non-MHC-restricted specificity for surface antigens. CARs 
specific for antigens overexpressed in different cancer types have been evaluated in clinical 
trials. However, first trials have reported treatment limiting toxicities due to strong cytotoxicity 
against normal tissues, also expressing the targeted antigens, and multiple cytokine release102-
104. However, good clinical responses and acceptable toxicities have been reported in a series of 
clinical studies using CD19-targeting CARs for the treatment of B-cell malignancies in adult and 
pediatric patients105-107. 
A different possibility is to generate ex vivo T cells expressing transgenic TCR, which, differently 
from CARs, allow targeting also tumor-associated intracellular antigens through MHC-I restricted 
epitope presentation.  Coding sequences for antigen-specific TCR can be either isolated from 
TILs of highly responsive patients or from T lymphocytes of transgenic mice expressing human 
HLA-A2, after immunization with the selected human tumor-associated antigen. This second 
approach offers broader applicability. However, since TCRs are generated in a mouse system, 
there is no thymic negative selection of TCR reactive towards all human proteins. The absence of 
central tolerance mechanisms may result in episodes of unintended cross-reactivity of the 
transgenic TCR against normal human tissue antigens3. Positive results using a  TCR originated in 
a transgenic mouse system were obtained in a clinical trial targeting the cancer-testis antigen 
NY-ESO-1, whose expression is restricted to germ cells and certain cancer types108. In this trial 
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objective clinical response was reported in 5/11 patients with melanoma and 4/6 patients with 
synovial cell sarcoma, after a single infusion of transgenic T cells, plus IL-2 administration and 
preconditioning chemotherapy, without the onset of autoimmune toxicity. 
Based on clinical studies conducted so far, ACT appears to be one of the most potent 
immunotherapy approaches, able to cause objective and durable clinical responses in patients 
refractory to standard therapies. Although most clinical successes using ACT were obtained in 
the treatment of melanoma, new technical advances in the generation of tumor specific 
cytotoxic T cells are gradually extending ACT efficacy to other cancer types. Importantly, as 
previously noticed, the development of effective ACT approaches is also dependent on the 
introduction of new strategies to modulate the immunosuppressive tumor microenveronnement 
in order to allow transferred T cells to expand end properly exert their function (fig. 2) 
 
 
 
Figure 2. Depletion of endogenous immunosuppressive cells is required for optimal 
efficacy of adoptive T cell transfer immunotherapy.   
Classical adoptive T cell therapy (ACT) strategy consists in the isolation of tumor-infiltrating 
lymphocytes from resected tumor specimens. Tumor-reactive T cells are selected and 
progressively expanded in vitro, and subsequently infused into patients. Prior to T cell infusion, 
patients undergo a lympho/myeloablating  treatment consisting in chemotherapy (fludarabine and 
cyclophosphamide) plus total body irradiation. Patient preconditioning with chemo/radiotherapy 
increases ACT efficacy by multiple mechanisms, including depletion of immunosuppressive 
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cellular elements (Tregs and MDSCs) which would otherwise impair the proliferation and function 
of transferred T cells. 
Adapted from : Restifo et al .Nat Rev immunol 2012. 
 
4. Use of drug and RNA delivery nanosystems in oncology 
 
The use of nano-sized platforms (nanocarriers) to deliver anticancer drugs has the potential to 
improve drug therapeutic index by: I) extending drug half-life by offering protection from drug 
degradation/metabolization  and reducing renal excretion; II) increase drug accumulation into 
the tumor site, while  preventing accumulation in most tissue; III)  increase selective cell uptake. 
The in vivo behavior of nanocarrier formulations depends on multiple factors, including 
nanocarrier size, shape, chemical composition, and surface charge. These features influence 
nanocarrier biodistribution, pharmacokinetic, interaction with the immune system, 
internalization by target cells, and intracellular fate. Such proprieties cannot be fully predicted 
based on nanocarrier composition and physico-chemical characteristics, and ultimately have to 
be determined empirically by experimental evaluation in suitable preclinical models. However, 
based on all the past research work in the field of cancer nanomedicine, some general rules have 
been established and are currently accepted as fundamental guidelines for the design of new 
nanocarriers formulations (fig. 3), which are discussed below.  
 
4.1.  Passive targeting of the tumor site: the EPR effect 
 
Nanocarrier size is recognized as one of the most important parameters regulating the in vivo 
fate of delivery systems. A size greater than 2 nm prevents the extravasation of nanoparticulated 
materials through cell-cell adherent junctions in the endothelial walls, and a size above 8 nm 
excludes particle from glomerular filtration in the kidney thus reducing clearance rates109. 
Nanocarriers below 200 nm are generally considered to preferentially accumulate within the 
tumor  site, rather than in most peripheral tissues, by the Enhanced Permeability Retention 
effect (EPR)109. The first evidences on the existence of the EPR effect was reported nearly 30 
years ago110 and since then this phenomenon has been largely investigated in mouse tumor 
models and used as rationale for the passive targeting of the tumor site by nanosystems.  The 
fundamentals of the EPR model rely on the irregular and leaky nature of tumor vasculature. 
Tumor vessels are formed by neo-angiogenetic processes triggered as soon as the tumor grows 
and lacks sufficient oxygen and nutrients supply by preexistent blood vessels, which induces cell 
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hypoxic response, necrosis and inflammation. Hypoxia response and inflammation leads to the 
release of pro-angiogenic factors (including VEGF, Ang2, and Fibroblast Growth Factor) that 
stimulate new vessel formations111. Due to the unbalanced network of factors orchestrating 
tumor-driven angiogenesis, tumor vessels are often irregular, discontinuous, with an abnormal 
or missing basement membrane, and are far more leaky than normal tissue vessels. Tumor 
vasculature is hence highly permeable and allows the extravasation of macromolecules normally 
excluded by most peripheral tissues112 Along with enhanced permeation of tumor vasculature, 
the EPR model presupposes the existence of an enhanced retention component, which relies on 
the defective lymphatic drainage of the tumor site. The intratumoral pressure cause the collapse 
of lymphatic vessels and the consequent absence of an efficient lymphatic drainage, especially in 
the center of the tumor mass. This results in the retention of essudated fluids into the tumor 
interstitium, from which they are slowly re-absorbed in the blood112. According to the EPR 
model, nanoparticulated material can more easily extravasate in the tumor site rather than in 
most normal tissues, and tend to be  retained in the tumor stroma, thus favoring uptake by 
tumor cells rather than by normal cells. 
The EPR has been broadly demonstrated in murine subcutaneous and orthotopic tumor models, 
but evidence of improved accumulation of nano-sized formulations in human cancers is still 
limited. Such limitation is in part due to the challenge in precisely evaluating biodistribution in 
humans, as compared to mouse models. A few studies evaluated in tumor biopsies or tumor 
exudates the concentration of Doxil®, a formulation of doxorubicin encapsulated into 100 nm 
PEGylated liposomes that has received FDA approval for the treatment of different human 
cancers113. In the first pharmacokinetic and biodistribution study on Doxil® in humans, the drug 
was quantified in malignant pleural effusions of cancer patients with ovarian, breast and non-
small cell lung cancer. Authors reported markedly enhanced drug amounts in tumor essudates 
following Doxil® administration than after free doxorubicin administration, thus indicating 
improved delivery to the tumor site114. However, in a recent paper reviewing biodistribution 
studies on doxorubicin liposomal formulations, liposomes were found to have an enhanced 
accumulation in tumor tissues with respect to plasma or surrounding tissues only in sarcoma 
patients, while this was not true for other tumor types115. In addition, an improved efficacy of 
PEGylated liposomal doxorubicin over free doxorubicin was reported only for Kaposi’s sarcoma 
and multiple myeloma patients, while the two formulations were equivalent on a more solid 
tumor as breast cancer116-118. Kaposi’s Sarcoma and multiple myeloma represents particular 
cases of poorly compact, highly vascularized and leaky tumors, which are easily accessible to 
nanoparticulated formulations and to which the EPR effect likely applies119. Other human tumors 
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may be less permeable and highly heterogeneous (including highly and poorly perfused zones), 
thus limiting the access of nanocarriers to the whole tumor mass. The paucity of evidence of 
improved efficacy of nanoparticulated formulations over standard anticancer therapy has  
recently challenged the universal validity of the EPR119. However, although most clinical 
evaluations of cancer nanomedicines did not unveil an improved efficacy over standard 
therapies, the use of some these formulations solved important toxicological issues and was 
therefore introduced into the clinical practice. Notably, Doxil® showed significantly reduced 
cardiotoxicity as compared with free doxorubicin, due to reduced exposure of cardiac tissue to 
the drug116,120. Abraxane® (nanoparticulated albumin-bound paclitaxel)   avoided the use of non-
ionic solvents (such as polyethylated castor oil) included in standard paclitaxel formulations, 
which were associated to severe toxicities; in this way Abraxane® formulation allowed to 
increase maximum tolerated paclitaxel doses and clinical efficacy in metastatic breast cancer121. 
 
4.2.  Mechanisms of  immune recognition of nanocarriers 
 
When designing tumor-targeted nanomedicines, a prolonged residence time of nanocarriers in 
the systemic circulation is generally  advantageous, since it favors the accumulation of carrier-
cargo complexes in the tumor tissue109. Doxil® is the prototype of long-term circulating 
formulation, with a markedly improved pharmacokinetic profile and a far lower clearance as 
compared with free doxorubicin114. 
In order to increase vascular residence, the delivery nanosystem needs to be protected from 
renal filtration, as said above, and from excessive uptake by cells of the immune system.  Once in 
the blood stream, nanocarriers tend to interact with serum proteins via various attractive forces, 
including hydrophobic/hyrdophylic and electrostatic bounds, resulting in the formation of a 
protein corona covering circulating particles, which includes immunoglobulin and complement 
fragments122,123.  Nanocarriers have sizes comparable to human viruses and since they are 
devoid of complement regulator proteins, which normally protect mammal cells by complement 
activation, they tend to be recognized as non-self and to activate complement pathways124. IgG 
adsorbed on nanocarrier surface and cleaved complement proteins act as opsonins and promote 
particle uptake by immune cells expressing FcγR and complement receptors, including tissue 
macrophages and circulating monocytes and neutrophils125. 
Since first works on nanomedicines, the complement system has been shown to be activated 
upon interaction with nanocarrier surface through both the classical and alternative 
pathway126,127. In general,  the rate of particle opsonization and clearance by the immune system  
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increases for highly charged particles as compared to neutral ones128. Notably, cationic 
nanocarriers strongly interact with anionic serum proteins, resulting in aggregation 
phenomena129. 
PEGylation, which consists in the decoration of a particle surface with  covalently bound, 
entrapped, or adsorbed polyethylene glycol (PEG) chains, has been widely  used to confer 
“stealth” proprieties, i.e. to mask nanocarriers from the immune system130. PEG is hydrophilic 
and neutrally charged and reduces both opsonization and non-specific binding to cell 
membranes by steric hindrance and shielding of charged or hydrophobic components in the 
formulation123. The long-term circulating proprieties of Doxil® are indeed attributed to the 
presence of PEG chains in the liposome outer layer. PEGylation however does not completely 
prevent particle recognition by the immune system. Reamarkably, PEGylated formulations, as 
Doxil®, still bear a residual ability to activate the complement system, and occasionally cause 
complement-related hypersensitivity reaction in patients124. In addition, macrophages have been 
shown to directly bind nanocarriers (notably liposomes) in an opsonin-independent  fashion via 
scavenger receptors, including CD14, CD36 and CD51/61, even in presence of a PEG coating128. 
Jones and coworkers examined the in vivo clearance of fluorescently-labeled, 300 nm PEGylated 
nanoparticles by myeloid cells in mice with different genetic backgrounds, evaluating both the 
plasmatic exposure and the differential uptake by distinct immune populations131.  BALB/C mice 
were found to have a faster clearance of particles from the blood, compared to C57BL/6 mice. In 
both mouse strains T and B lymphocytes showed a poor nanoparticle uptake, while spleen 
macrophages had higher levels of particle internalization as compared to most other splenic 
immune subsets131. Remarkably, the degree of particle uptake by monocytes and granulocytes 
was dramatically different between the two strains, since monocytes showed the strongest 
particle internalization in the blood of C57BL/6 mice, while granulocytes were the population 
with the highest particle uptake in both the blood and spleen of BALB/C mice131. According to 
this study, both mononuclear phagocytes and granulocytes are involved in particle clearance, 
which begins in the blood, before reaching blood filtration sites as the spleen and the liver.  
Interestingly, the relative importance of each immune population on nanoparticle clearance may 
be strain-related. These differences were explained based on the alternative bias of specific 
mouse strains towards a Th1-oriented (C57BL/6) or a Th2-oriented (BALB/C) immune 
polarization131. However, many of the biodistribution studies are performed in healthy mice, 
while pathological states may influence immune response polarization and might result in a 
different pattern of nanopaticle uptake by immune populations, which should be then evaluated 
for each specific disease model.  
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Features promoting particle recognition by immune cells, which are carefully avoided when 
designing nanosystems for the delivery of tumor-targeted drugs, becomes instead desirable 
when the main aim is targeting immune cells. However, in approaches aimed at targeting tumor-
infiltrating myeloid cells, the use of stealth, long-circulating delivery nanosystems  may also be 
advantageous since, as discussed so far, it promotes accumulation within the tumor site. 
 
 
 
Figure  3. Main factors affecting drug delivery to tumors by nanosystems.  
Delivery nanosystems must have a size above 8 nm to avoid both extravasation in normal tissues 
with tight endothelial junctions and glomerular filtration in the kidney.  In addition, shielding 
polymers ad polyethylene glycol (PEG) can be used to minimize nanocarrier opsonization and 
uptake by immune cells. Reduced nanocarrier clearance by both renal excretion and immune-
mediated destruction results in prolonged residence times in blood circulation. In turn, long-
circulating nanocarriers accumulate more efficiently in the tumor site by the enhanced 
permeability and retention Effect (EPR), which relies on the higher permeability of tumors vessels 
with respect to most peripheral tissues. Once target tissues are reached, the drug payload may 
be released either in the extracellular space or upon cell uptake and carrier disruption.   
From: Dawidczyk al, . J Control Release 2014. 
 
4.3.  Passive versus active tumor targeting 
 
Along with passive targeting approaches, nanosystems for active tumor cell targeting have been 
developed. Active targeting relies on the recognition of ligands overexpressed by cancer cells or 
tumor vessels by cognate molecules decorating nanocarrier surface, including antibodies, 
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antibody fragments, peptides, nucleic acid ligands and small molecules115. The design of actively 
targeted formulations presents further complexity as compared with systems for passive 
targeting, since multiple parameters as nanocarrier architecture, ligand conjugation chemistry 
and the choice of targeted ligands all contribute to determine nanosystem efficacy. This 
enhanced complexity is also associated to increased costs when the approach is translated from 
preclinical models to the clinic and ultimately to the pharmaceutical market132. Currently there 
are no FDA-approved targeted nanomedicine formulations, but a few systems are being 
evaluated in phase I/II clinical trials115. In the field of active targeting, targeting ligands expressed 
by multiple cancer types are generally more appealing, since the broader market potentials of 
these formulations compensate the costs associated to experimental evaluations. Examples of 
these ligands are the Transferrine Receptor  and the Prostatic Membrane Antigen (PSMA)115, the 
latter being expressed on prostate cancer calls and on tumor vessels of most solid tumors, but 
not in normal endothelium133. As an example, Docetaxel-loaded nanoparticles targeting PSMA 
were found to produce an enhanced drug accumulation into tumor tissues and more potent 
antitumor efficacy as compared to free docetaxel in mouse tumor models, and had a favorable 
pharmacokinetic profile in multiple preclinical models134. This nanoparticle-based formulation is 
currently in early phase of clinical evaluation and preliminary data indicate the presence of 
objective responses to the treatment134. 
Remarkably, targeting tumor cells by recognition of tumor-specific ligands, requires first particle 
accumulation into target tissue and hence the previously discussed proprieties, such as reduced 
renal and immune-mediated clearance, extended vascular residence and improved 
accumulation at the tumor site, are still required for both actively targeted formulations and 
passive targeting approaches. 
Strategies for active targeting of tumor cells will not be extensively described in this context, 
since the primary focus of the present work will be the targeting of tumor-associated myeloid 
cells. However, general considerations about the challenges and cost/benefit issues of active 
targeting approaches presented above also apply to the targeting of myeloid cells, which is 
discussed in paragraph 5. 
 
4.4.  Challenges in therapeutic RNA delivery 
 
Therapeutic silencing of selected genes can be achieved by exploiting RNA interference (RNAi) 
mechanisms. RNAi cellular machinery operate on both RNA duplexes of exogenous origins and 
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endogenous RNA molecules, such as microRNAs (miRNAs). miRNAs are transcribed as long stem 
loop molecules termed pri-miRNAs, and processed into pre-miRNAs through a microprocessor 
complex involving the endonuclease Drosha. These pre-miRNAs are then exported to the 
cytoplasm by the exportin-5 transporter, cleaved into small RNA duplexes of approximately 22 
nucleotides by the endonuclease Dicer, and ultimately loaded into the RNA-induced silencing 
complex (RISC). Argonaute 2, a multifunctional protein that is part of the RISC, unwinds the 
double strand RNA (dsRNA) and one of the strands (guide strand) is selected, while the opposite 
strand is degraded (passenger strand). The activated RISC complex binds to mRNAs with 
sequence complementarity to the guide strand resulting in target mRNA silencing by RNA 
endonucleolytic cleavage, translational repression or destabilization by deadenylation135,136. The 
two latter mechanisms are more common for naturally occurring miRNAs, which usually have 
partial complementarity to target sequences, while artificial dsRNA of exogenous origins are 
usually designed to be exactly complementary to target mRNAs and results in their direct 
cleavage. The dsRNA of exogenous origin can enter the cellular RNAi machinery at different 
levels: short interfering RNAs (siRNA) are dsRNA oligo of about 22 nt that can be directly loaded 
onto the RISC. In a similar way, artificial miRNA mimics can be introduced into cell cytoplasm and 
directly bind to the RISC complex. Short hairpin RNAs (shRNA) can be generated by transcription 
of transgenes carried by plasmids or lentiviral vectors integrated in the genome and thus 
undergo an analogous processing pathway to endogenous miRNA precursors. The shRNA 
molecules can also be chemically synthesized and transfected into cells, where they require to 
be processed before being loaded on RISC136. 
In vivo RNA delivery approaches have to overcome multiple physiological barriers. First, naked 
RNA tend be rapidly degraded by serum nucleases after introduction in the systemic circulations, 
so it needs to be protected by nuclease attack by structural modifications and/or encapsulation 
into delivery systems. Many RNA chemical modification are routinely used to stabilize RNA 
molecules, including substitution of 2’ oxygen with a fluorine atom (fluorination), 2’-O-
methylation, locked nucleic acids (LNA), unlockednucleic acids (UNA)  and phosphorothioated 
backbones137. Some of these modifications, as 2’-O-methylation and LNA modifications, have 
also been reported to reduce siRNA immunogenicity in vivo by preventing activation of Toll-like 
receptors (TLR), such as TLR7138,139. Chemical modifications may allow facing stability and 
immunogenicity issues, and may be sufficient to achieve efficient in vivo nucleic acid delivery for 
certain applications. For instance, successful naked LNA delivery to hepatocytes has been shown 
in non-human primates models140,141.  
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However, for other applications the use of RNA delivery systems may be essential to overcome 
further physiological barriers and achieve meaningful in vivo gene silencing. As anticancer drugs, 
also naked nucleic acids are smaller that the renal filtration limit and are hence rapidly cleared 
from the blood circulation142. Moreover, anticancer RNAi therapeutics, as anticancer drugs, 
require accumulation into the tumor site by passive or active targeting approaches. To extend 
blood circulation half-life and consequently accumulation into the tumor site, particle PEGylation 
is largely exploited for RNA nanocarriers, as for drug delivery systems (see paragraph 4.2 ). 
Naked RNA molecules does not readily cross the cell membrane, due to their size and negative 
charge, and delivery systems can improve cell internalization of RNA molecule. Moreover, since 
internalization mostly occurs by endocytic mechanisms, delivery vehicles have also to promote 
RNA escape from the endosomal compartments, in order to avoid its premature degradation137. 
Cationic delivery systems, including cationic lipid nanoparticles and cationic polymers, are 
particularly suitable to this purpose since they electrostatically interact with the negatively 
charged cell surface and promote membrane wrapping and cell internalization. Moreover, they 
have been reported to induce endosomal escape by destabilizing phospholipid layers of the 
endosomal membranes or by a “proton sponge effect”123. This latter effect consists in the 
buffering the endosomal lumen during endosomal acidification process, which results in an 
increased ionic concentration, endosome swelling and rupture. In addition, delivery systems may 
be specifically designed to respond to endosomal acidification by becoming membrane-
disruptive, for instance by taking advantage of pH-responsive disruption of PEG shells143. 
However, mechanisms of endosomal escape of delivery nanosystems are still not fully 
understood, and for many systems the effective RNA release into the cytoplasm remains to be 
empirically determined. 
Several RNAi-based therapeutic have been evaluated in clinical trials for the treatment of various 
diseases, including cancer137. Such therapeutics are based on different delivery vehicles, 
including cationic polymers (as cyclodextrin and polyethyleneimine-PEI), liposomes and other 
lipid nanoparticles, and siRNA-polymer conjugates137,142. 
An example of effective RNA delivery systems used in cancer therapy is the ALN–VSP drug, 
developed at the Alnylam Pharmaceuticals and currently under clinical evaluation. ALN-VSP 
consists in lipid nanoparticle encapsulating two different siRNA, targeting VEGF and kinesin 
spindle protein (KSP).  ALN-VSP particle contains ionizable lipids, which acquire positive charge 
at acidic endosomal pH (thus favoring interaction with endosomal membranes and endosomal 
escape) and also include PEGylated lipids, in order to minimize immune recognition and increase 
vascular residence137,144. siRNAs encapsulated in ALN-VPS include O’2-methylated bases, to 
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improve nuclease stability and reduce immunogenicity144.  Moreover, these particles have a size 
between 80 and 100 nm, which favors accumulation in organs with large endothelial 
fenestration as spleen and liver, and  permeable tumor tissues144. ALN-VSP was preclinically 
evaluated in a mouse liver tumor model, where effective down-regulation of target genes by 
RNAi mechanism was demonstrated. Moreover pharmacologic effects of VEGF and KSP 
inhibition was reported, which consisted in a reduced tumor vasculature and block of cell 
mitosis, respectively, and an overall improvement of mice survival144. A clinical evaluation in 
patients bearing different cancer types with liver involvement, showed antitumor efficacy in 
both hepatic and extraepatic sites after repeated drug administration, including one complete 
response. In addition, effective cleavage of target mRNA in tumor biopsies was reported, and 
drug administration had favorable toxicological profile, thus supporting the further investigation 
of this drug in clinical setting144. 
Nucleic acid delivery systems specifically aimed at targeting myeloid cell for cancer 
immunomodulation and immunotherapy will be discussed in the following sections. 
 
5. Targeting immunosuppressive and tumor-promoting myeloid cells 
using nanocarriers 
 
Nanocarriers are known to be easily opsonized and uptaken by myeloid cells in the circulation 
and in blood filtration organs (spleen and liver) primarily by non-specific binding of circulating 
IgG and complement activation, as discussed in detail in paragraph 4.2. Thus, myeloid cells can 
be targeted using delivery nanosystems without the need of functionalization with actively 
targeting molecules, although this latter approach may increase the degree of uptake by 
selected cell populations as compared with other cells, as discussed below. Myeloid cell 
targeting approaches with applications in cancer immunotherapy include DC-targeted vaccines 
and drug or RNAi-based therapeutics to deplete or functionally modulate immunosuppressive 
and tumor-promoting cells, as MDSCs ant tumor macrophages. 
The use of nanoparticulated vaccines as compared with protein/peptide-based vaccines has the 
avantage of I) increasing antigen uptake by DCs, by exploiting the size and pathogen-like 
appearance of nanosystems that favor their internalization by myeloid cells; II) prolong antigen 
release in vivo; III) simultaneously deliver antigens and adjuvant moieties, as TLR ligands145. 
Nanotechnology-based cancer vaccination approaches will not be extensively discussed here, 
since the development of new cancer vaccines is not among the purposes of this work. Next 
sections will review a series of studies on either drug or RNA delivery nanosystems aimed at 
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targeting MDSCs and TAMs, and present some possible future approaches for the development 
of MDSC- and TAM-targeted nanomedicines. In addition, also nanosystems developed to target 
monocytes and neutrophils in acute and chronic inflammation models, which could be 
translated to MDSC-targeting in cancer, will be discussed. 
 
5.1.  Targeting monocytes and  neutrophils 
 
A few works have reported a partially selective targeting of inflammatory (Ly6Chigh) monocytes 
by different nanocarrier formulations  in mouse models of inflammatory diseases.  It is worth to 
note that M-MDSCs expanded in mouse tumor models bear phenotypic and morphologic 
similarities with Ly6Chigh inflammatory monocytes10. A current view  is that M-MDSCs actually 
represents, at least in part, a pathological  functional state of inflammatory monocytes, which 
acquire tumor-induced immunosuppressive functions. Similarly, PMN-MDSC may represent an 
altered functional state of normal granulocytes, as further discussed in paragraph 1.  Therefore, 
strategies developed to target inflammatory monocytes or neutrophils in model of acute and 
chronic inflammation are also likely to found application in M-MDSC and PMN-MDSC targeting in 
tumor models.  
Leushener et al. reported a 70-80 nm PEGylated lipid nanoparticle with a preferential 
internalization by Ly6Chigh inflammatory monocytes, although also other myeloid subsets in 
blood and lymphoid organs (including Ly6Clow non-inflammatory monocytes, granulocytes, DCs 
and macrophages) showed particle uptake146. Such delivery system had been selected among 
several other prototypes based on its strong ability to deliver siRNA molecules, following a high 
throughput in vitro and in vivo screening procedure147. In the work by Leushner et al. this 
optimized RNA delivery system was employed to deliver a siRNA specific for the CC-chemokine 
receptor type 2 (CCR2), which mediates Ly6Chigh monocyte recruitment to inflammation sites146 
Of note, this signaling axis is likely involved also in the recruitment of human CD14+CD16- 
monocytes, which share phenotypic features and homing potential with mouse Ly6Chigh 
inflammatory monocytes148. CCR2-specific siRNA delivery resulted in the successful down-
regulation of the target gene in Ly6Chigh monocytes,  reduced mobilization and recruitment of 
these cells, and attenuation of pathological symptoms in multiple disease models in which the 
intense and prolonged monocyte activation has a pathologic impact146. Notably, reduced 
inflammatory monocyte recruitment resulted in an attenuation of myocardial ischemia-
reperfusion injury in a mouse model of myocardial infarction, reduced plaque size in an 
atherosclerosis model, and improved the acceptance of pancreatic islets allograft in diabetic 
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mice. In mice bearing EL4 subcutaneous lymphomas, prolonged siRNA administration, started as 
soon as tumors were palpable, resulted in the reduction of monocyte-derived tumor 
macrophages and delayed tumor growth146. More recently, another work reported a different 
drug delivery nanosystem formulated from poly(lactic-co-glycolic) acid (PLGA) polymer with a 
size around 200 nm, which was uptaken by circulating and spleen monocytes with higher 
efficiency as compared with neutrophils149. Such system was employed to deliver the statin drug 
pitavastatin to inflammatory monocytes, resulting in reduced MCP-1 (CCR2 ligand) expression 
and macrophage infiltration in atherosclerotic plaques, smaller plaque size, and decreased 
incidence of plaque destabilization and rupture in a mouse model of atherosclerosis149. 
Small (30 nm) PEGylated  nanoparticles injected intradermally were reported to  efficiently 
travel through the lymphatics, reach systemic blood circulation, and accumulate in monocytes in 
blood and multiple organs150. Macrophages were the secondly most targeted population, while 
other immune cells including T and B lymphocytes, granulocytes and DC subsets had 
comparatively less particle internalization, except for isolated populations residing in specific 
sites. The same particles, when administered to mice bearing subcutaneous lymphomas, showed 
propensity to accumulate in M-MDSCs in both the tumor and lymphoid organs150. This 
observation further supports the concept discussed above, that nanocarriers with preferential 
uptake by monocytes are also likely suitable to target M-MDSCs in tumor models. 
Although most efforts to selectively target myeloid cells have been done using nanocarriers with 
enhanced uptake by DCs or monocyte/macrophages, also nanocarrier with granulocyte-
targeting proprieties have been reported. 300 nm PEGylated nanoparticles with cylindrical shape 
were found to strongly accumulate in blood and spleen granulocytes in healthy BALB/c mice, 
while in mice with a different genetic background (C57BL/6) the same particles were mostly 
uptaken by monocytes and macrophages131(this work is discussed  more extensively in 
paragraph 4.2).  A recent work by Wang et al. described the use of albumin-based 100 nm 
nanoparticles to target activated neutrophils adhering to vessels walls at sites of local TNF-α-
induced inflammation151,152. In this model either non-activated circulating neutrophils or 
activated monocytes adhering to inflamed vessels showed minimal nanoparticle internalization. 
Nanoparticles loaded with piceatannol, a pharmacologic inhibitor of Syk (a kinase involved in 
regulation of neutrophil adhesion and migration), reduced neutrophil infiltration in lungs in a 
model of LPS-induced acute lung injury, and showed better efficacy as compared to the free 
drug152. Particle uptake was shown to be partially dependent on Fcγ-RIII expression on activated 
neutrophils152. According to this work, neutrophil ability to uptake opsonized nanoparticles may 
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be dependent on Fcγ receptor upregulation upon inflammatory stimuli, while steady-state 
neutrophils have reduced ability to recognize and internalize circulating particles. 
 
5.2.  Targeting MDSCs 
 
Along with nanocarriers targeting monocytes and neutrophils in healthy mice or non-tumor 
disease models, specific nanotechnology-based MDSC targeting strategies have been developed 
and evaluated in tumor models. 
M-MDSC apoptosis was induced using RNA aptamers specifically blocking the IL-4 receptor α (IL-
4Rα/CD124)153. IL4Rα-targeting aptamers preferentially bound to M-MDSCs and TAMs in mouse 
tumors and to M-MDSCs in the spleen153, which bear an higher expression  of the targeted 
receptor as compared to granuloytic cells25. Cytokine binding to the IL-4Rα mediates STAT6 
activation, resulting in the upregulation of ARG-1 and increased immunosuppressive functions of 
MDSCs and TAMs10. The IL-4/STAT6 pathways seems to mediate also pro-survival signals in 
MDSCs, since its inhibition by IL-4Rα blocking aptamers caused increased MDSC apoptosis. Of 
note, MDSC and TAM targeting by IL4Rα-blocking aptamers was associated to an increased 
number of tumor-infiltrating T cells and a delayed tumor growth in a 4T1 mammary carcinoma 
model153. 
A nanoparticulated adjuvant containing gangliosides and bacterial components, termed very 
small size proteoliposomes (VSSPs)154, was found to induce  MDSCs maturation in mouse tumor 
models155. Notably, the use of VSSPs was shown both to modulate the phenotype of splenic 
MDSCs and reduce their ability to suppress T cytotoxic cell activation155.  
Together with already reported MDSC-targeting nanosystems, many other nanotechnology-
based approaches can be envisaged, based on the encapsulation of different drugs that have 
been proved to deplete or functionally modulate MDSCs. Indeed, using nanocarriers to increase 
drug delivery to immunosuppressive myeloid cells may allow reaching immunomodulatory 
effects with higher selectivity, enhanced potency, and lower off-target toxicity.  
Among candidate drugs, some chemotherapeutic drugs have a known activity on MDSCs at very 
low doses, even in absence of a directed tumor cytotoxicity; the list includes sunitinib, sorafenib, 
bortezomib, gemcitabine, fludarabine, 5-fluorouracyl21,156 and docetaxel157. In addition, 
trabectedin, a drug recently approved for cancer treatment, was shown to induce a selective 
monocyte/macrophage apoptosis in multiple mouse tumor models and in sarcoma patients, 
including mouse splenic M-MDSCs53. 
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A different drug candidate is the all-trans-retinoic acid (ATRA), a derivative of vitamin A, which is 
currently primarily employed in the treatment of acute myeloid leukemia. This drug has long 
been known to promote the differentiation of MDSCs into mature DCs, macrophages and 
granulocytes158. Strikingly, in a pilot study on metastatic renal cell carcinoma, patients having 
high plasma levels of ATRA after oral administration reported a decrease in circulating immature 
myeloid cells as compared to pre-treatment values159. In the same patients, circulating 
mononuclear cells displayed an improved ability to stimulate T cell activation in vitro159. 
However, ATRA administration present pharmacological issues. Notably, treatment with ATRA 
results in a substantial drop in plasmatic drug levels following chronic administration, due to 
multiple factors including  induced drug enzymatic hyper catabolism and decreased intestinal 
absorption160. Liposomal and polymeric micelle formulations of ATRA, administered 
intravenously, were shown to maintain higher ATRA plasma levels as compared with oral or 
intravenous administration of the free drug161,162. ATRA delivery nanosystems may thus be 
appealing both as therapeutics for the treatment of acute myeloid leukemia and 
immunomodulating agents to target MDSCs in solid tumors. 
In addition, the relief of MDSC-mediated immunosuppression has been achieved in preclinical 
models by employing drugs that exert a double inhibitory effect on iNOS and ARG1, such as 
phosphodiesterase-5(PDE5) inhibitors98, nitroaspirin163 and AT3840. Sildenafil, a PDE5 inhibitor, 
was reported to reduce iNOS and ARG1 expression, although the pharmacological mechanism of 
inhibition was not deeply investigated98. In mouse model, Sildenafil reduced tumor-induce 
immunosuppression and potentiated the efficacy of ACT treatments98. 
Nitroaspirin is a modified aspirin molecule, covalently linked to a NO-releasing group. 
Mechanistically, nitroaspirine activity on MDSCs involves both the NO-donor group and the 
salicylic portion of the drug. The NO release exerts a negative feedback inhibition on both iNOS 
activity and expression, while the acetylsalicylic acid is thought to interfere with the signaling 
pathways that induce ARG1 upregulation163. Remarkably, nitroaspirin was shown to act 
synergistically with anti-cancer vaccination approaches, resulting in an extended mouse 
survival163. 
 AT38 was developed by introducing chemical modifications in the nitroaspirin molecule in order 
to enhance its pharmacological activity on MDSCs40. AT38 administration to tumor-bearing mice 
strongly reduced the production of peroxynitrite in tumors, thus reducing the nitration status of 
CCL2 and favoring T cytotoxic lymphocyte recruitment by this chemokine40. The use of 
nanocarriers to enhance the accumulation of these drugs in tumors and  promote their uptake 
by MDSCs might allow to further improve treatment efficacy.  
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5.3.  Targeting TAMs 
 
Liposomes have long been employed as delivery vehicles to target macrophages. General 
interactions between delivery nanosystems and macrophages, as well with other immune cells, 
have been described in detail in paragraph 4.2. In addition, liposome composition and surface 
charge may specifically influence particle uptake by macrophages. Notably, the presence of 
negatively charged phospholipids as phosphatidylserine and phosphatidylglycerol is known to 
enhance liposome internalization by macrophages, as compared with neutral liposomes, at least 
in part by engagement of scavenger receptors on macrophage membrane164. 
Liposomes loaded with bisphosphonates, as clodronate, have been used to deplete 
macrophages since the end of the 80’s, by exploiting the preferential uptake of liposomes by 
these cells165. Remarkably, TAM depletion by clodronate-loaded liposomes  was repeatedly 
shown  to exert antitumor effects by reducing tumor growth, angiogenesis  and metastatization 
in murine cancer models166-170. 
Although macrophages are naturally prone to bind and internalize liposomes and other 
nanocarriers, the use of active targeting strategies may allow achieving a more potent and 
specific macrophage targeting. Nanocarrier mannosilation, i.e. surface decoration with 
mannoside groups recognized by the mannose receptor (MR, CD206), was reported to improve 
macrophage targeting, both in vitro and in vivo164. MR ligands are particularly suitable for TAM 
targeting, since this receptor is overexpressed by M2-like TAMs as compared with M1 
macrophages61 (see paragraph 2). Mannosylated nanoparticles equipped with an acid-sensitive 
PEG shell were reported to preferential target TAMs, with reduced accumulation in liver and 
spleen171. In this system, PEG-sensitive molecules were spontaneously hydrolyzed in the acidic 
tumor microenvironment, thus exposing the MR targeting ligands171. 
A single domain antibody derived from heavy-chain antibodies found in Camelids (termed 
“nanobody”) with MR specificity, was generated by Mohavedi and coworkers172. This  nanobody 
was found to accumulate in subcutaneous mouse tumor model, through specific binding on MR 
expressed on stromal cells, mainly consisting of TAMs172. The MR-specific nanobody was 
successfully employed to image TAMs in vivo172 and might be used to functionalize drug or 
nucleic acid delivery nanosystem to enhance TAM targeting. 
A second receptor overexpressed on M2-like TAMs is the hemoglobin scavenger receptor 
(CD163)61. Surface functionalization of liposomes with anti-CD163 antibodies was shown to 
increase the efficacy of macrophage targeting in vitro173, although  in vivo efficacy was not 
evaluated. 
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Porous silicon nanoparticles decorated with anti-Ly6C antibodies were used to target Ly6C 
expressing cells in ortothotopic pancreatic cancer xenografts in mice, including endothelial cells 
and monocyte/macrophages174. In vivo, fluorescently labeled Ly6C-targeting particles exhibited 
preferential intra-tumor accumulation with respect to other organs, and co-localized with target 
stromal cells174. 
TAMs were also targeted using nanoparticle encapsulating hydrazinocurcumin (HC), a synthetic 
analog of the polyphenol compound curcumin, which exert an inhibitory activity on STAT3 
phosphorilation175. HC-nanoparticles were found to be able to re-educate M2-like macrophage 
towards a M1-like phenotype in vitro. Moreover, treatment of mice bearing 4T1 mammary 
carcinoma with these particles resulted in the reduction of tumor growth, angiogenesis and lung 
metastasis formation, possibly due to a double inhibitory effect on STAT3-dependent pro-tumor 
pathways in cancer cells and STAT3-mediated M2 polarization in TAMs175. 
Besides molecules already reported to be coupled with nanocarriers, also other active targeting 
strategies may be envisaged based on recently described peptides and antibodies with 
macrophage specificity. A M2macrophage-targeting peptide, named M2pep, was identified to 
bind preferentially to M2-like macrophages rather than M1-like macrophages and DCs in vitro  
and target TAMs, but not liver and spleen macrophages in vivo176. 
Remarkably, an anti CSF-1R antibody was recently developed and pre-clinically and clinically 
evaluated as anticancer therapeutic agent177. Such antibody binds to the CSF-1R (CD115) that is a 
key regulator of macrophage survival, differentiation and migration178. Blocking the CSFR-1 
receptor by antagonist antibodies, with mouse or human specificity, strongly reduced tumor-
infiltrating macrophages in mouse tumor models and in human tumors of different histological 
types177. The use of these antibodies might also be extended to the functionalization of 
macrophage-directed nanosystems, possibly allowing potentiating the effects obtained by the 
anti CSF-1R antibody alone.   
In addition to all the reported TAM-directed strategies, it must be pointed out that therapeutic 
approaches aimed at killing monocytes in blood, lymphoid organs and tumor sites, or intended 
at preventing their mobilization and recruitment to tumors, ultimately result in a reduced TAM 
accumulation. Indeed, CCR2 RNAi silencing by siRNA-delivering nanoparticle, by blocking 
monocyte recruitment through the CCL2/CCR2 signaling axis, caused an impaired accumulation 
of tumor-infiltrating macrophages146(see also paragraph 5.1). The chemotherapeutic drug 
trabectedin, which was reported to selectively trigger apoptosis pathways on mouse and human 
circulating monocytes, significantly reduced TAM frequency in both mouse tumors and human 
sarcoma specimens53. 
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Aim 
 
Since the discovery of the immunosuppressive and tumor-promoting function of myeloid cells, 
including myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs), 
a number of different strategies either to eliminate or functionally modulate these cells have 
been investigated.  Among MDSC-targeting strategies, low dose chemotherapy with selected 
drugs has a considerable interest due to its simplicity and the possibility of a rapid translation to 
the clinic. The use of biocompatible nanosystems to encapsulate and deliver chemotherapeutics 
to tumor cells was shown to reduce toxicity and increase drug accumulation in the tumor site. 
Using such nanocarriers to increase drug delivery to immunosuppressive myeloid cells, besides 
tumor cells, is a less explored approach, which might allow reaching immunomodulatory effects 
with higher selectivity, enhanced potency, and lower off-target toxicity.  
In addition to cell depletion by cytotoxic drugs, it is possible to modulate tumor-conditioned 
myeloid cells by switching off key genes controlling either differentiation or function of these 
cells. The impact of such approach has been widely demonstrated using mouse knockout 
models. However, its translation into therapeutic strategies requires the efficient in vivo delivery 
to myeloid cells of short RNA molecules (as siRNAs, shRNAs or miRNAs) able to downregulate 
target gene expression by RNA interference mechanisms. The use of nanosystems for RNA 
delivery can be advantageous to obtain potent in vivo gene regulation, due to the improved 
stability, increased circulation times and enhanced targeting efficiency that RNA-nanocarrier 
complexes may provide with respect to naked RNA. 
In the present work, we aimed at developing new approaches to target immunosuppressive and 
tumor-promoting myeloid cells in cancer, by taking advantage of nanosystems for drug and 
nucleic acid delivery. To this aim, we investigated the immunomodulatory effects of low dose 
chemotherapy with a modified gemcitabine molecule encapsulated into lipid nanocapsules. 
Moreover, we also exploited a nanotechnology-based tool for in vivo gene silencing suitable to 
modulate the expression of relevant target genes in myeloid cells. 
This work was carried out in the framework of a project founded by the European Community 
grant Euronanomed and was based on the collaboration between our laboratory and two 
research groups, which were responsible for the synthesis of delivery nanosystems, namely the 
group of  Jean Pierre Benoit  (LUNAM Université , Micro et Nanomédecines Biomimétiques, 
INSERM – U1066 IBS-CHU, F-49933 Angers, France) and of Maria Josè  Alonso (Dept. Pharmacy 
and Pharmaceutical Technology and Center for Research in Molecular Medicine and Chronic 
Diseases, Campus Vida, Universidad de Santiago de Compostela, Spain). 
38 
 
  
39 
 
Results 
 
Biodistribution, pharmacokinetic, and cell uptake of lipid nanocapsules 
(LNCs) 
 
Lipid Nanocapsules (LNCs) were prepared by a patented method, originally developed in the 
laboratory of J.P. Benoit and based on a phase inversion temperature process179. These 
nanocapsules were composed of an oily core surrounded by a tensioactive rigid layer containing 
polyethylene glycol (PEG) chains,  and had a size between 65 and 55 nm.  
We first characterized the in vivo biodistribution (BD), pharmacokinetic (PK) and cell targeting 
proprieties of LNCs, in order to define whether this delivery system was suitable to efficiently 
reach target organs (spleen and tumor) and cells (MDSCs and TAMs). For tracking purposes, we 
initially used LNCs loaded with the fluorescent dye DiD (DiD-LNCs) without any drug cargo. DiD 
dye was chosen due to its amphiphilic nature, which allows the dye to be trapped in the 
surfactant shell of LNCs  and prevents  its release, unless the nanocarrier is broken down after 
cell uptake180.  LNC BD and PK proprieties were characterized either after intravenous (IV) or 
subcutaneous (SC) injection. The SC route was considered since SC injection of nanoparticulated 
formulations has been associated to the formation of subcutaneous depots from which the drug 
is slowly absorbed in the systemic circulation, resulting in a slower clearance and a prolonged 
systemic exposure to low drug doses181,182. A small size (below 100 nm) was shown to favor 
nanoparticle absorption by the lymphatic drainage of the injection site, a propriety mostly 
exploited for the design of nanoparticulated vaccines150,183,184. Interestingly, small (30 nm) 
PEGylated nanoparticles injected intradermally were reported to travel efficiently through the 
lymphatics, reach systemic blood circulation, and accumulate in monocytic (M)-MDSCs in the 
tumor and secondary lymphoid organs150. Due to their small size, LNCs were thus expected to 
have good lymphatic absorption proprieties through the SC route. 
BD and PK experiments were performed in healthy mice. LNCs loaded with the fluorescent dye 
DiD (free of the drug cargo) were injected either SC or IV and a semi-quantitative measurement 
of DiD fluorescence in plasma and explanted organs was performed. This semi-quantitative 
analysis allowed us to compare LNC accumulation in the same organ at sequential time points 
and upon either SC or IV administration route. However, due to the different photon absorption 
properties of each organ, a direct comparison of DiD fluorescence signal among different organs 
was not possible by this technique.  
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Upon IV administration, LNCs rapidly distributed to most organs (fig. 1A). In comparison, SC 
injection resulted in a weaker DiD signal at earlier time points (1-8 hours), except for lymph 
nodes near the injection site (axillary, cervical and brachial lymph nodes), which were likely 
reached by direct lymphatic drainage (fig. 1B).  At later time points (24-96 hours), SC-injected 
LNCs had a distribution pattern similar to IV-injected LNCs, characterized by a substantial 
accumulation in the liver and spleen at 24-48 hours, which decreased at 96 hours, and a 
sustained presence in lymph nodes over time (fig. 1C and D). Of note, at 24 hours DiD 
fluorescence in the spleen tended to be higher after IV injection than after SC injection, while at 
48 hours DiD signal in spleens was comparable after either IV or SC administration (at both time 
points differences between IV and SC groups were not statistically significant). 
 
 
 
 
Figure 1. Biodistribution of DiD-loaded LNCs in healthy mice.  
Healthy, nude mice were injected with DiD-loaded LNCs either intravenously (IV, panel A and C) 
or subcutaneously (SC, panel B and D). Average DiD fluorescence signal in explanted organs at 
different time points is shown. At 1h, 4h and 8h, differences in DiD fluorescence between IV and 
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SC groups were statistically significant for kidney, liver, spleen, lung, heart, stomach, intestine 
and inguinal LNs (p<0.05, Student’s t test). At 24h, 48h and 96h, differences in DiD signal in the 
spleen between IV and SC groups were not statistically significant (p>0.05, Student’s t test). Data 
are reported as means  SD; n=5 mice per group. 
 
Pharmacokinetic analysis revealed a far lower plasmatic exposure of SC-injected LNCs compared 
to IV-injected (fig. 2), which resulted in a lower area under the curve (AUC) associated to the SC 
route as compared with the IV route (10.94 μg/ml/h and 174.2 μg/ml/h, respectively). 
Moreover, IV-injected LNCs were cleared more rapidly from the organism than SC-injected LNCs, 
since calculated half-life (t1/2 elimination) in plasma was 19 hours and 32 hours, respectively (fig. 
2).  
In summary, BD and PK studies showed that LNCs are slowly and probably incompletely 
absorbed in the blood circulation upon SC administration. The SC route is also associated with a 
slower clearance from the organism, possibly due to a sustained drug absorption from a 
subcutaneous depot over time, which compensates for LNC elimination. Importantly, SC 
administration avoids a high plasmatic exposure of nanocapsules and the consequent 
accumulation in off-target organs at early time points (1-8 hours). Moreover, despite the slow 
LNC absorption after SC administration, LNCs exhibited comparable accumulation levels in the 
spleen at 48 hours after either IV or SC injection. 
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Figure 2. DiD plasmatic concentrations following injection and calculated pharmacokinetic 
parameters for DiD-loaded LNCs. 
Healthy, nude mice were injected with DiD-loaded LNCs either  intravenously (IV) or 
subcutanously (SC) and blood samples were collected at sequential time points (1h, 4h, 8h, 24h, 
48h, and 96h ). Data are reported as means  SD; n=5 mice per group 
 
In order to assess whether LNCs were able to reach the tumor site after both IV and SC injection, 
we injected mice bearing established, EG7-OVA subcutaneous tumors with DiD-LNCs. To assure 
that LNCs passed through the systemic circulation (and not just by diffusion in nearby tissues) 
before reaching the tumor mass, SC injection was performed on the opposite flank with respect 
to tumor injection site. DiD fluorescence was detected on fixed tissue sections by confocal 
microscopy. Figure 3 shows representative images of spleen and tumor sections and 
quantification of DiD mean fluorescence intensity (MFI), 24 hours after either SC or IV LNC 
injection.  Consistently with biodistribution data on healthy mice, a stronger DiD signal was 
detected in the spleen upon IV injection compared to SC injection at the 24 hour time point. IV 
administration resulted in a more marked DiD accumulation within the tumor mass, although 
DiD fluorescence was detectable also after SC LNC injection. In the spleen, DiD signal was 
primarily detected in close proximity of vessel-like structure and in the red pulp, while lymphoid 
follicles were largely DiD negative. 
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Figure 3. Distribution of DiD-loaded LNCs in spleens and tumors of EG7-OVA tumor-
bearing mice. 
A,B,C,D. Representative confocal microscopy images of tissue sections at 24 hours from DiD-
loaded LNC (DiD-LNCs) intravenous (IV) or subcutaneous (SC)  injection in C57BL/6 mice 
bearing ~50 mm
2
 EG7-OVA tumors. SC injection was performed on the opposite flank with 
respect to tumor mass. Lymphoid follicles in the spleen are identified as zones with high nuclei 
density surrounded by CD11b
+ 
myeloid cells. Nuclei in gray (DAPI staining), CD11b in green, DiD 
in blue. 40x magnification A. Spleen after DiD-LNCs IV injection. B. Spleen after DiD-LNCs SC 
injection. C. Tumor after DiD-LNCs IV injection.  D. Tumor after DiD-LNCs SC injection. E. Mean 
Fluorescence intensity (MFI) of DiD in spleens and tumor sections, calculated on a set of 
randomly selected field per section.  Means  SE, n= 3 mice per group. *p<0.05 **p<0.01, 
Student’s t-test 
 
We subsequently evaluated whether LNCs were differentially uptaken by distinct immune cell 
populations. To this aim, mice bearing EG7-OVA tumors were SC injected with DiD-LNCs and  the 
percentage of DiD+ cells within splenic and tumor-infiltrating cells was determined by flow 
cytometry. Myeloid cell populations in the spleen and tumors were defined as described in 
figure 4. The greatest LNC internalization was observed in tumor-infiltrating monocytic (M-) 
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MDSCs and macrophages and in splenic M-MDSCs (fig. 5A). Lower percentages of DiD+ cells were 
found within polymorphonuclear/granulocytic (PMN-) MDSCs in the tumor and spleen, and 
F4/80high red-pulp macrophages and dendritic cells (DCs) in the spleen. The uptake of DiD-LNCs 
by T CD4+ and T CD8+ cells was negligible.  
LNCs were not fully selective for myeloid cells, since they were also uptaken by CD11b- cells in 
the tumor, possibly including stromal cells and tumor cells (fig. 5B). However, the immune cell 
uptake pattern was promising and prompted us to investigate the use of LNCs as tool to target 
immunosuppressive monocytic/macrophagic cells in the spleen and tumor site. 
 
 
 
Figure 4. Gating strategy for the identification of myeloid cell populations in the spleen and 
tumor. 
A. Dot plots showing the gating of red pulp macrophages (CD11b
low/neg 
F4/80
high
), 
polymorphonuclear/granulocytic (PMN-) MDSCs (CD11b
+
Ly6G
+
Ly6C
int
) and monocytic (M-) 
MDSCs (CD11b
+
Ly6G
- 
Ly6C
high
) in the spleen. M-MDSCs are also F4/80
low
, and partially express 
the CD115 marker. B. Gating of DCs in the spleen (CD11c
+
MHCII
+
). C. Gating of PMN-MDSCs 
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(CD11b
+
Ly6G
+
Ly6C
int
), M-MDSCs (CD11b
+
Ly6G
-
Ly6C
high
) and macrophages (CD11b
+
Ly6G
- 
Ly6C
low/- 
F4/80
+
) in the tumor. All analysis were performed after selection of living single cells by 
morphologic gating, doublets exclusion and dead cell exclusion by LIVE/DEAD® dye staining. 
Reported dot plots refer to spleens and tumors of C57BL/6 mice bearing ~50 mm
2 
EG7-OVA 
tumors. 
 
 
 
 
Figure 5. Uptake of DiD-loaded LNCs by splenic and tumor-infiltrating cell populations.  
LNCs were injected SC, on the flank opposite to tumor mass, in C57BL/6 mice bearing EG7-OVA 
tumors; mice were sacrificed 24 hours later. A. Percent of DiD
+
 cells within indicated myeloid cell 
populations and within T lymphocytes (CD3
+
CD8
+
 and CD3
+
CD4
+
 cells). B. Percent of DiD
+
 cells 
within CD11b
+ 
(myeloid cells) and CD11b
- 
cells in the tumor. Means SE, n=4 mice. 
 
 
GemC12-loaded LNCs selectively deplete monocytic MDSCs and show 
improved efficacy over gemcitabine hydrochloride  
 
LNCs were loaded with a modified form of gemcitabine, obtained by adding a single 12-carbon 
(C12) alkyl chain to the amine group of gemcitabine molecule. This modified gemcitabine, 
termed gemcitabine-C12 (GemC12), was protected from inactivation by deamination, thus 
improving in vivo stability, and had an increased lipophilicity that allowed encapsulation into 
LNCs185. Free gemcitabine hydrochloride (GemHCl) was previously reported to cause the 
depletion of splenic and tumor-infiltrating CD11b+Gr1+ myeloid cells in different mouse tumor 
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models, after administration of a drug dose ranging from 50 to 120 mg/kg21,156,186-188. We treated 
mice bearing established EG7-OVA tumors with a single dose of 11 mg/kg GemC12 loaded into 
LNCs (LNC-GemC12), a dosage at which free GemHCl was not expected to cause significant 
toxicity on myeloid cells. Such drug dose was chosen with the intent of disclosing the increased 
efficacy associated with the use of LNC-GemC12 compared to free GemHCl. 
Mice were treated with 11 mg/kg LNC-GemC12, either injected IV or SC (on the flank opposite to 
tumor mass), or received an equal dose of GemHCl IV.  LNC-GemC12 administration resulted in a 
substantial reduction of M-MDSC in the tumor and spleen after 24 hours from treatment. Other 
myeloid subsets showed no significant variations, except for a slight tendency of tumor PMN-
MDSC to increase, likely compensating for the loss of M-MDSCs, and a minor decrease in DCs 
within the spleen (fig. 6).  Unexpectedly, also GemHCl at the 11 mg/kg dose significantly 
depleted monocytic cells, while PMN-MDSCs and macrophages were not reduced (fig. 6). 
Conversely, higher gemcitabine doses are known to significantly decrease both monocytic and 
granulocytic MDSCs, as previously reported21,156. None of the given treatments resulted in a 
significant reduction of either splenic or tumor-infiltrating T cells (CD3+CD8+ and CD3+CD4+ cells, 
fig. 6). Remarkably, the strongest M-MDSC depletion was observed in mice treated with SC-
injected LNC-GemC12, possibly depending on the sustained release proprieties identified for 
LNCs administered SC.   
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Figure 6. Subcutaneously-administered, low dose LNC-GemC12 strongly deplete spleen 
and tumor-infiltrating M-MDSCs. 
Data are presented as frequency of myeloid cell subsets and T cells (CD3
+
CD8
+
 and CD3
+
CD4
+
 
cells)  in the tumor (A) and in the spleen (B) after 24 hours from the subcutaneous (SC) or 
intravenous (IV) administration of indicated treatments. Means SE, n=4 mice per group.*p<0.05 
**p<0.01, Student’s t-test. Statistical comparisons are between each treatment group and the 
untreated controls, unless differently indicated. 
 
This observation prompted us to investigate further the immunomodulatory proprieties of SC-
injected LNC-GemC12. To this aim, we measured the frequency of different splenic and tumor-
infiltrating myeloid cell subsets at sequential time points following administration of LNC-
GemC12, GemHCl or free GemC12 solutions (11 mg/kg). To exclude biases between LNC-
GemC12 and free drugs related to the administration route, all treatments were given SC, on the 
side opposite to tumor mass. At the time of sacrifice, tumor sizes were comparable among the 
different groups (fig. 7D), thus excluding the possibility of differences in myeloid cell expansion 
due to a delayed tumor growth following drug administration. Within the tumor site, M-MDSCs 
were strongly reduced at 24 and 48 hours from LNC-GemC12 administration (fig. 7A). In 
addition, GemC12 and GemHCl decreased M-MDSC frequency in the tumor after 24 hours from 
drug injection, although to a less extent as compared with LNC-GemC12. Remarkably, M-MDSCs 
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recovered more rapidly in GemC12 and GemHCl-treated mice than in the LNC-GemC12 group 
and reached comparable levels to untreated mice at the 48-hour time point (fig. 7A). In all 
treatment groups, normal M-MDSC frequency in the tumor was completely restored after 72 
hours following drug injection. PMN-MDSCs exhibited no significant variations over the 
considered time points, while tumor macrophages had a slight tendency to increase at the later 
time points, notably in the GemHCl group (fig. 7A). 
M-MDSC frequency variations in the spleen mirrored the effects observed among tumor-
infiltrating M-MDSCs. At 24 hours, M-MDSCs were reduced in all treatment groups, while they 
faster recovered after GemC12 and GemHCl administration, as compared to the LNC-GemC12 
group (fig. 7B). Interestingly, when splenic M-MDSC population was analyzed according to 
CD115 marker expression, the administered treatments were found to exert a greater impact on 
CD115+ cells as compared to the CD115- fraction. At the 24 hour time point, the CD115+ subset 
had an average  7.7, 5.2 and 5.6–fold decrease in the LNC-GemC12, GemHCl and GemC12 
groups, respectively, as compared with the control untreated group (fig. 7C). At the same time 
point, the CD115- subset displayed a milder variation, since average fold-decreases  in the same 
groups were 2, 2.2 and 2.4, respectively (fig. 7C).  Moreover, at the 48 hours time point, mice 
treated with LNC-GemC12 still had a significant reduction of CD115+ cells, but not of the CD115- 
subset.  Such observation might suggest the existence of two M-MDSC subsets differing for 
CD115 expression, with distinct sensitivity to gemcitabine cytotoxic activity. 
Only in the GemHCl group PMN-MDSCs were also significantly reduced after 24 hours from drug 
injection (fig. 7B), supporting the lower selectivity of free GemHCl for monocytic cells with 
respect to LNC-GemC12.  In all treated animals, spleen PMN-MDSCs were significantly decreased 
at the 72 hours time point (fig. 7B). Such delayed PMN-MDSC reduction might be interpreted as 
a secondary effect of spleen M-MDSC depletion, since this latter population has been reported 
to include precursor cells with the ability to differentiate in both monocytes/macrophages and 
granulocytic cells21. However, further studies are required to demonstrate rigorously this 
hypothesis. T cell frequencies in both the spleen and the tumor were not decreased in all 
considered time points (data not shown). 
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Figure 7. Low dose LNC-GemC12 administration results in an enhanced and prolonged M-
MDSC depletion.  
A. Frequency of M-MDSCs, PMN-MDSCs and macrophages in the tumor at 24, 48 and 72 hours 
from the administration of indicated treatments. B. Frequency of M-MDSCs, PMN-MDSCs and 
red pulp macrophages (CD11b
low/neg
 F480
high
)  in the spleen at 24, 48 and 72 hours from the 
administration of indicated treatments. C. Frequency of CD115
+
 and CD115
-
 M-MDSC subsets in 
the spleen at the indicated time points. D. Tumor surface (mm
2
) at the time of sacrifice. 
All data are reported as means  SE, n=4 mice per group.*p<0.05 **p<0.01 ***p<0.001, Student’s 
t-test. Statistical comparison is between each treatment group and the untreated controls, unless 
differently indicated. 
 
In summary, low dose GemC12 loaded into LNCs selectively depleted splenic and tumor-
infiltrating monocytic  cells with improved efficacy, both in terms of effect intensity and 
duration, as compared to gemcitabine hydrochloride. Moreover, in the experiment reported in 
figure 7 no substantial differences  were observed between free GemC12 and GemHCl, 
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suggesting that the enhanced efficacy of LNC-GemC12 over GemHCl cannot be exclusively 
attributed to the use of a modified gemcitabine molecule, but rather to factors specifically 
related to the employed nanocarriers.  
In mouse cancer models, both tumor-infiltrating and splenic CD11b+ cells are known to exert 
immunosuppressive functions, which can be measured through ex vivo suppression assays20,25. 
Among different subsets, M-MDSCs were shown to be endowed with markedly stronger 
immunosuppressive abilities in comparison to  PMN-MDSCs20,22,44. In addition, in a recent work 
from our group, the immunomodulatory activity of MDSC-depleting chemotherapy was found to 
primarily rely on the elimination of monocytic cells, while granulocytic cells played a minor 
role21. We hence reasoned that the selective depletion of monocytic cells using low dose LNC-
GemC12 could result in the relief of MDSC-induced immunosuppression and be used for 
therapeutic purposes. To investigate these points, we first measured the immunosuppressive 
activity of tumor-infiltrating CD11b+ cells after SC administration of 11 mg/kg LNC-GemC12 or 
GemHCl to EG7-OVA tumor bearing mice. Twenty four hours after drug administration, total 
CD11b+ cells were isolated from tumor masses by immunomagnetic sorting and co-cultured with 
CFSE-labelled OTI splenocytes, in presence of the SIINFEKL ovalbumine antigenic peptide. The 
proliferation of antigen-activated T CD8+ cells was measured based on CFSE dilution during cell 
replication. As shown in figure 8, CD11b+ cells isolated from LNC-GemC12-treated mice had a 
reduced ability to suppress T cell proliferation as compared to control CD11b+ cells isolated from 
untreated mice.  Conversely, CD11b+cells  from mice that received GemHCl exerted a 
comparable suppressive activity to control CD11b+ cells. The selective depletion of the 
monocytic MDSC subset by LNC-GemC12 was thus found to impair the overall 
immunosuppressive activity of tumor-infiltrating CD11b+cells. 
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Figure 8. Low dose LNC-GemC12 administration impairs the immunosuppressive activity 
of tumor-infiltrating  myeloid cells. 
CD45.2
+ 
C57BL/6 mice were injected subcutaneously with either LNC-GemC12 or GemHCl when 
tumor surfaces reached ~50 mm
2
, and sacrificed 24 hours later. CD45.1
+ 
OTI splenocytes were 
labeled with CFSE and cultured in presence of the SIINFEKL ovalbumine (OVA) peptide to induce 
antigen-specific activation of T CD8
+ 
cells. CD11b
+
 myeloid cells isolated from tumor masses 
were added to splenocyte cultures. CFSE dilution upon T cell proliferation was measured by flow 
cytometry after 3 days of culture. Data for co-cultures with 24% CD11b
+ 
cells are shown 
 A. Histograms of CFSE fluorescence (% of maximum cell count vs fluorescence intensity) in the 
CD8
+
CD45.1
+
 gate. Control cultures without CD11b
+
 cells (gray curve) correspond to the highest 
CFSE dilution, indicating maximum T cell proliferation. Other curves represent CFSE 
fluorescence after T cell co-culture with CD11b
+
cells from untreated mice (red), CD11b
+
 cells from 
LNC-GemC12-treated mice (blue), and CD11b
+
 cells from GemHCl-treated mice (green). B. T cell 
proliferation is expressed as fraction of T cells that underwent the indicated number of cell cycles 
based on CFSE dilution. In control cell culture without OVA peptide (No pept) T cell proliferation 
was minimal, indicating absence of non-specific T cell activation. All other conditions refer to T 
cells activated in presence of their cognate peptide. The graph represents T cell proliferation in 
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cell cultures without CD11b
+
 cells (No CD11b
+
) or with CD11b
+
 cells from not treated mice, mice 
treated with LNC-GemC12 or mice treated with GemHCl. Representative graph from one of two 
repeated experiments. 
 
 
Preconditioning with low dose LNC-GemC12 improves mouse survival 
following adoptive T cell therapy  
 
The relief of tumor-induced immunosuppression is known to improve the efficacy of passive 
immunotherapy strategies, including the adoptive transfer of tumor-specific T cells (adoptive T 
cell therapy, ACT)21,40,98, by creating a more favorable environment for T cell recruitment, 
proliferation and function. We hence wondered whether M-MDSC depletion by low dose LNC-
GemC12 administration could be used to precondition tumor-bearing mice prior to ACT in order 
to enhance mouse survival. 
Since LNC-GemC12-mediated M-MDSC depletion had a maximum 48h duration, we investigated 
whether repeated LNC administrations after T cell transfer could be used to extend the time 
window of attenuated immunosuppression and enhance T cell expansion upon adoptive 
transfer. Three different LNC administration schedules were tested in combination with ACT. The 
frequency of transferred T cells in lymph nodes and tumor masses and the IFNγ production upon 
antigen re-stimulation were evaluated as predictive parameters for therapy efficacy. ACT 
protocol consisted in the IV infusion of in vitro pre-activated T cells specifically recognizing the 
ovalbumin (OVA) model antigen expressed by EG7-OVA tumor cells. The frequency of  overall 
CD8+CD45+ cells and CD8+CD45+IFNγ+ cells in both lymph nodes and tumors was dramatically 
reduced when mice were treated with one or two LNC injection after T cells infusion (schedules 
II and III, fig. 9), as compared to mice receiving either ACT alone or one single LNC-GemC12 dose 
prior to ACT (schedule I, fig. 9). This result indicated the existence of a deleterious effect of LNC-
GemC12 administration in the days immediately following T cell infusion, likely due to a direct 
drug cytotoxicity on transferred T cells.  Conversely, following one single LNC-GemC12 injection 
24 hours before ACT (schedule I, fig 9.), the frequency of overall and IFNγ-producing 
CD8+CD54.1+ T cells was not reduced in lymph nodes and tended to increase in tumors, as 
compared with control mice receiving ACT alone, although statistical significance was not 
reached. Of note, in mice receiving ACT alone or ACT plus single dose LNC-GemC12, tumor-
infiltrating CD8+CD54.1+ T cells produced IFNγ even without re-stimulation with their cognate 
peptide, thus suggesting that these cells were already functionally activated in vivo (fig.9).  
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Figure 9. Evaluation of three different schedules of LNC-GemC12 administration in 
combination with adoptive T cell therapy (ACT). 
A. LNC-GemC12 (11 mg/kg) was administered subcutaneously to CD45.2
+ 
C57BL/6 mice bearing 
EG7-OVA tumors, either at day 8 (schedule I), at day 8 and at day 12 (schedule II), or at day 8, 
10 and 12 (schedule III) following tumor injection. ACT was given at day 9 and consisted in the 
intravenous infusion of pre-activated, OVA-specific CD8
+
CD45.1
+ 
T cells. Mice were sacrificed at 
day 15 and cells from lymph nodes and tumors were cultured 16 hours, either in presence or 
absence of the specific OVA peptide, before flow cytometry staining. B, C. Percentage of 
CD8
+
CD45.1
+
 T cells  and of CD8
+
CD45.1
+ 
IFNγ
+
 T cells in lymph nodes (B) and in tumors (C) 
after LNC-GemC12 treatment according to schedule I, II or III, plus ACT. Data are expressed as 
means  SE, n=5 mice per group. *p<0.05 **p<0.01, Mann-Whitney Rank Sum Test. Statistical 
comparison is between each group and the control group receiving ACT alone, unless differently 
indicated. 
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Based on these data, we next evaluated the impact of a single LNC-GemC12 or GemHCl 
administration prior to T cell infusion on mice survival after ACT (schedule reported in fig. 10A). 
GemHCl was administered both SC, as LNC-GemC12, and IV, since the IV route currently 
represents the golden standard for GemHCl administration in clinic. As expected, ACT with pre-
activated OVA-specific T cells, which have an extremely high affinity for the ovalbumin antigen, 
delayed tumor growth and significantly improved mice survival even without any 
preconditioning treatment (fig. 10B,C and D). However, combination of LNC-GemC12 with ACT 
resulted in a further reduction of tumor burden and  extended survival as compared to mice 
receiving ACT alone (fig 10B, C and D). Remarkably, the survival of mice preconditioned with 
GemHCl, either administered SC or IV, did not significantly differ from that of control mice 
receiving only ACT. Interestingly, the therapeutic efficacy of combined GemHCl administration 
and ACT was better after SC rather than IV GemHCl administration, as indicated by the more 
pronounced tumor mass reduction in mice treated with GemHCl SC (fig.10B). This latter 
observation excludes that the improved efficacy of LNC-GemC12 over GemHCl could be due to 
the use of the SC route, instead of the more commonly employed IV route, for GemHCl 
administration. 
Taken together, these results demonstrate that low dose LNC-GemC12 exert an 
immonumodulatory activity based on selective M-MDSC depletion, which can be exploited to 
attenuate tumor-induced immunosuppression and improve the efficacy of ACT. Of note, 
although also GemHCl administration at the same dose induced M-MDSC reduction, this 
treatment had a reduced potency in term of both intensity and duration of target cell depletion 
as compared with LNC-GemC12, and did not result in a survival improvement when used to 
precondition mice prior to ACT. 
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Figure 10. Preconditioning with low dose LNC-GemC12 improves mice survival after 
adoptive T cell therapy (ACT). 
A. Therapeutic schedule: mice bearing established EG7-OVA tumors were treated either with 
subcutaneous (SC) LNC-GemC12, subcutaneous GemHCl or intravenous (IV) GemHCl at 11 
mg/kg drug dose; 24 hours after chemotherapy, mice received an IV infusion of 0.25x10
6
 pre-
activated, OVA-specific cytotoxic T cells (ACT). Tumor growth was monitored until the end-point 
tumor size of 150 mm
2
, at which mice were euthanized. B. Tumor growth after treatment 
administration, expressed as tumor surface (mm
2
) vs time (means SE).n=8 mice per group. 
*p<0.05 **p<0.01 ***p<0.001, comparison with control group receiving ACT alone, Student’s t-
test. C and D. Overall survival curves (panel C and D refers to the same experiment). All 
treatments resulted in an improved survival with respect to untreated mice (p<0.001). However, 
only mice receiving LNC-GemC12 plus ACT had a significantly extended survival compared to 
mice treated with ACT alone (p= 0.015);n=8 mice per group. Statistical analysis was performed 
with Log-Rank test with p-value correction for pairwise multiple comparisons (Holm-Sidak 
method). 
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Development of a nanosystem suitable for gene silencing in myeloid 
cells consisting in polyarginine nanocapsules loaded with fluorinated 
shRNAs 
 
Post-transcriptional in vivo gene silencing based on RNA interference (RNAi) mechanisms is 
currently being explored for the therapy of various diseases, including cancer137. Naked and 
unmodified RNA is easily attacked by serum nucleases, rapidly cleared by renal filtration, may be 
immunogenic and has poor ability to cross cell membranes and reach the cytoplasm. Effective in 
vivo RNA delivery requires RNA chemical modifications and/or complexation with delivery 
vehicles composed of biocompatible, nontoxic materials137. Cationic polymers, often as 
component of nanocarrier formulations, are broadly used for RNA delivery since they readily 
bind to nucleic acids via electrostatic attractions and interact with the negatively charged 
glycocalyx on cell surface, thus favoring cell internalization. However, positively charged 
nanocarriers may also be associated with significant cytotoxicity189 and may form aggregates in 
blood due to electrostatic interaction with anionic serum proteins129. 
With the intent of developing a RNA delivery system suitable to target tumor-conditioned 
myeloid cells, we assessed the toxicity of 4 different formulations of nanocapsules on bone 
marrow-derived MDSCs (BM-MDSCs). BM-MDSC differentiation was achieved through four days 
culture of bone marrow cells in presence of GM-CSF and IL-6 stimuli, as previously reported99. 
Nanocapsules (NCs) were added at day 0 and the ratio between viable recovered cell numbers at 
day 4 and plated cell numbers at day 0 was calculated as indicative parameter of NC toxicity.  
Formulation 1 (NC1) was a control formulation devoid of cationic polymers for nucleic acid 
complexation and composed of an oily core and an external hydrophilic shell of hyaluronic acid 
(HA). NC 2 and 3 also contained HA as one of the components and both included protamines 
(small, arginine-rich, proteins) as cationic polymers for nucleic acid binding.  NC 2 mainly differed 
from NC 3 for the presence of polyethylene glycol (PEG), a widely employed biocompatible, 
neutrally charged polymer, as shielding component, and for the absence of succinate and 
sodium cholate in the formulation. NC 4 was a completely different formulation, consisting in an 
oily core surrounded by a surfactant layer containing PEG chains, with an outer shell of 
polyarginine for RNA complexation (polyarginine NCs, PolyArg NCs).  As shown in figure 9, BM-
MDSC differentiation in presence of NC 2 and 4 allowed a cell recovery near 100% in all the 
range of tested NC concentrations, while NC 1 and 3 were associated with a dramatic drop in cell 
recovery at higher NC concentrations. 
Despite its net positive charge, NC 4 (PolyArg NCs, ζ potential +42 mV) was found to produce the 
lowest toxicity on BM-MDSC cultures. Moreover, PolyArg NCs did not show any tendency 
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towards aggregation in serum-containing media (data from M.J. Alonso laboratory, not shown). 
Interestingly, polyarginine is a known cell-penetrating peptide and has been reported to 
promote both cell internalization of delivery systems and endosomal escape190,191. We thus 
decided to investigate further PolyArg NCs as nanosystem for RNA delivery into myeloid cells. 
To achieve a stronger in vivo gene silencing by RNAi mechanisms, we chose to load PolyArg NCs 
with stabilized, RNase-resistant RNA molecules, instead of conventional unmodified RNA oligos. 
To this aim, we set up and optimized a protocol for the in vitro transcription of RNase-A 
resistant, fluorinated short hairpin (sh)RNAs, which could be efficiently loaded onto PolyArg NCs. 
The workflow for fluorinated shRNA synthesis is summarized in figure 12 and further details are 
provided in the “Materials and methods” section. Of note, shRNA synthesis by this technique 
allowed to obtain consistent amounts of fluorinated RNA, suitable for in vivo use.  
 
 
 
 
Figure 11. In vitro cytotoxicity assessment on BM-MDSCs of nanocapsule formulations for 
nucleic acid delivery. 
A. Bone marrow cells from healthy mice were cultured for four days in presence of GM-CSF and 
IL-6 to induce BM-MDSC differentiation (see text and “Materials and methods” for further details). 
Nanocapsules were added at day 0 and the number of viable cells was determined at day 4. Data 
are expressed as percent ratio of recovered cell numbers at day 4 on plated cell numbers at day 
0, normalized with respect to maximum cell recovery in control cell cultures without nanocapsules. 
B. Table summarizing the tested formulations with indication of nanocapsule size and ζ potential. 
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Figure 12. Workflow for the synthesis of RNase A-resistant, fluorinated short hairpin (sh) 
RNAs to be loaded on PolyArg NCs. 
Specifically designed, self-annealing primers were used to obtain a dsDNA template by PCR 
extension. This template was then used for the in vitro transcription (IVT) of fluorinated shRNAs, 
using the Durascribe T7 transcription kit (Epicenter). The dsDNA was removed by DNAse I 
digestion and shRNAs were purified by spin columns and loaded onto PolyArg NCs. Further 
details are provided in the “Materials and methods” section. 
 
 
The shRNA-loaded polyarginine nanocapsules down-regulate C/EBPβ 
expression in myeloid cells in vitro and in vivo 
 
To evaluate the efficacy of shRNA-loaded PolyArg NCs as gene silencing system, we selected a 
target gene with a relevant function in MDSC biology. The selected gene was the mouse 
CCAAT/enhancer binding protein (C/EBP)β transcription  factor, which was previously shown to 
be required for the induction of MDSC expansion and  immunosuppressive program99. 
Interestingly, C/EBPβ ablation in conditional knockout mice was reported to dramatically 
improve mice survival after ACT, thus supporting the relevance of C/EBPβ pathway as 
therapeutic target  in cancer immunotherapy99.  
A shRNA with sequence complementarity to mouse C/EBPβ mRNA (shC/EBPβ) and a scrambled 
control shRNA (shCTRL) were designed and generated according to the protocol described in 
figure 12.  To assess PolyArg NCs efficacy in delivering shC/EBPβ in vitro to myeloid cells, we 
trasfected an immortalized MDSC cell line (MSC1192) using either PolyArg NCs or a commercial 
trasfection reagent (Lipofectamine RNAi Max®, Invitrogen). Cells were transfected with 30 nM 
shRNA and harvested 24 hours later. The 30 nM shRNA concentration was chosen basing on 
previous titration experiments that identified this shRNA concentration as the one resulting in 
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the strongest sequence-specific C/EBPβ  down-regulation (data not shown). As shown in figure 
13, shC/EBPβ transfection with both PolyArg NCs and Lipofectamine caused a significative 
reduction of C/EBPβ mRNA levels.  
 
 
 
 
Figure 13.  PolyArg NCs loaded with C/EBPβ-targeting shRNA downregulate C/EBPβ 
mRNA levels in the MSC1 cell line. 
MSC1 cells were transfected with the C/EBPβ-targeting shRNA (shC/EBPβ) or  a scrambled 
shRNA (shCTRL) either loaded on PolyArg NCs (NC-shC/EBPβ) or complexed with 
Lipofectamine RNAi Max® reagent (Invitrogen), and harvested 24 hours later. C/EBPβ mRNA 
levels were quantified by RT-qPCR and normalized with respect to an endogenous control 
(Rn18S). Data are expressed as relative quantification (R.Q.), normalized to non-transfected (not 
treated) cells. Means SE (n=3). Statistical comparison between each group and the untreated 
control, *p<0.05, ***p<0.001, Student’s t-test. 
 
After demonstrating that shC/EBPβ-loaded NCs (NC-shC/EBPβ) were functional in vitro, we 
evaluated the in vivo efficacy in a mouse tumor model. The MCA203 sarcoma was selected 
because of the relevant C/EBPβ expression in both tumor infiltrating and splenic myeloid cells, as 
previously reported99. Mice bearing established MCA203 tumors were intravenously injected 
with NC-shC/EBPβ or non-loaded NCs. Treatments were started at day 11 from tumor injection 
when tumor surfaces were approximatively 35 mm2, and repeated 3 times with 48 hours 
intervals (RNA dose= 20 μg/mouse/treatment, fig. 14 A). Animals were sacrificed after 48 hours 
from the last treatment and CD11b+ myeloid cells were isolated from spleens and tumors by 
immunomagnetic sorting.  C/EBPβ mRNA  levels were significantly reduced  in both splenic and 
tumor-infiltrating CD11b+  cells in mice treated with NC-shC/EBPβ as compared to controls (fig. 
14B).  C/EBPβ downregulation was around 50% in splenic myeloid cells and 30% in tumor-
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infiltrating myeloid cells.  No evident signs of toxicity were observed during the treatment 
period. 
To investigate whether C/EBPβ downregulation, whilst for a short time period, had an impact on 
tumor-associated myelopoiesis, we performed a phenotypic analysis of myeloid cell subsets in 
lymphoid organs (spleen and bone marrow) and at the tumor site. While our analysis revealed 
no differences in bone marrow and splenic myeloid populations (data not shown), a significant 
decrease in the frequency of tumor-associated macrophages was observed in the NC-shC/EBPβ 
group compared to controls (fig. 14 C). Such macrophage reduction was paralleled by a 
significant increase in monocytic cells (phenotypically definable as M-MDSCs), thus suggesting 
that C/EBPβ downregulation by RNAi might result in a partial impairment of monocyte 
differentiation into tumor-associated macrophages. 
 
 
 
 
Figure 14. PolyArg NCs loaded with C/EBPβ-targeting shRNA downregulate C/EBPβ  
expression in vivo.  
A. Schematic representation of the treatment schedule. C57BL/6 mice bearing MCA203 
subcutanous tumors received three intravenous injection of PolyArg NCs, either unloaded or 
loaded with C/EBPβ-targeting shRNA (20 μg RNA/mouse/treatment). Mice were sacrificed 48 
hours after the last treatment. B. C/EBPβ mRNA levels within CD11b
+ 
cells isolated from spleens 
and tumors of mice treated with either unloaded  NCs or NCs loaded with the C/EBPβ-targeting 
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shRNA (NC-shC/EBPβ). C/EBPβ mRNA levels were quantified by RT-qPCR and normalized to 
an endogenous control (Rn18S). Data (means SE) are expressed as relative quantification 
(R.Q.) normalized to the average cycle threshold value for the control group receiving unloaded 
NCs. C. Percentage of M-MDSCs, PMN-MDSC and macrophages on total CD11b
+ 
cells within the 
tumor (means SE). Cell populations were defined according to the gating strategy reported in 
figure 4C. n=4 mice (unloaded NC) and n=3 mice (NC-shC/EBPβ). *p<0.05 **p<0.01 ***p<0.001, 
Student’s t-test. 
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Discussion 
 
MDSC depletion or inhibition of MDSC-associated mechanisms of immunosuppression is known 
to improve the efficacy of cancer immunotherapy approaches in preclinical models, including 
ACT21,40,98 and cancer vaccines193. In addition, clinical trials evaluating the efficacy of MDSC-
targeted pharmacological agents, combined with either immunotherapeutics or conventional 
chemotherapeutics, are currently ongoing (www.clinicaltrials.gov NCT01697800; NCT02259231; 
NCT01803152). Due to the therapeutic interest in investigating increasingly effective approaches 
to reduce MDSC-mediated immunosuppression, we sought to evaluate the use of a recently 
developed encapsulated gemcitabine formulation, GemC12-loaded lipid nanocapsules (LNC-
GemC12)185, as MDSC targeting agent. Notably, we aimed at investigating whether low dose 
LNC-GemC12  can be effectively combined with ACT approaches to improve therapy efficacy.  
Since the approval of the first nano-drug for cancer therapy, Doxil® (liposomal Doxorubicin) in 
1995, cancer nanomedicine has received growing interest, and nanocarrier-based drug 
formulations have been shown to improve drug pharmacological proprieties by increasing drug 
stability, vascular residence, accumulation into tumor tissues and by reducing off-target 
toxicity109,119. The use of delivery nanosystems to modulate specifically immune populations is a 
much less explored research area, which has recently received growing attention as promising 
tool to improve cancer immunotherapy145. 
Remarkably, gemcitabine hydrochloride (GemHCl), the current gold standard formulation for 
gemcitabine, was already reported to deplete spleen and tumor infiltrating MDSCs in mouse 
models21,156,186-188,194. We hence wondered whether drug loading into lipid nanocapsules might 
result in a more selective and/or potent MDSC targeting and provide therapeutic advantages as 
compared with GemHCl.  
In the present work, we considerably decreased gemcitabine dose with respect to previous 
reports, i.e. 50-60 mg/kg186,188 and 120 mg/kg21,156,187,194, in the attempt of disclosing the 
enhanced efficacy of LNC-GemC12 over GemHCl.  
In our model, both low dose (11 mg/kg) LNC-GemC12 and GemHCl depleted  M-MDSC subsets in 
the spleen and tumor, while leaving unchanged or minimally affecting the frequency of other 
immune cell subsets, including PMN-MDSCs, macrophages, DCs, and T lymphocytes. Conversely, 
a 120 mg/kg GemHCl dose was previously reported to cause substantial and comparable 
depletion of both M- and PMN-MDSCs in mouse tumor models21,156. Remarkably, in our 
experiments tumor-infiltrating M-MDSCs were more drastically decreased following LNC-
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GemC12 subcutanous (SC) administration as compared with intravenous (IV) LNC-GemC12 
injection or either IV or SC GemHCl administration, as shown in figure 6 and 7. Moreover, when 
we monitored myeloid cell frequency variations at sequential time points, SC LNC-GemC12 
administration was found to produce a more durable M-MDSC depletion in the tumor than SC 
GemHCl.  
More importantly, LNC-GemC12 treatment was associated with an attenuation of tumor-
infiltrating MDSC suppressive function toward T cells (as shown in figure 8), and to an improved 
mouse survival when combined with an ACT protocol (data reported in figure 10). Conversely, 
GemHCl administration at the same dose did not result in a modulation of MDSC suppressive 
function nor in a survival advantage in the combined treatment schedule with ACT. 
The selective depletion of M-MDSCs using very low drug doses is a potentially attractive 
immunomodulatory strategy, due to the strong immunosuppressive function of this cell subset 
in cancer. Indeed, in multiple tumor models M-MDSCs were found to be more potent 
suppressors of T cell response when compared with PMN-MDSCs 20-22,25,44. 
In addition, in a previous work by our group, the relief of MDSC-induced immunosuppression 
following 5-fluorouracile (5-FU) chemotherapy was shown to be mainly dependent on the 
elimination M-MDSCs, while PMN-MDSCs played a minor role21. Strikingly, in this latter work the 
adoptive transfer of M-MDSCs, but not of PMN-MDSCs, resulted in the neutralization of the 
beneficial effect of mouse preconditioning with 5-FU in an ACT schedule21. 
The higher sensitivity of M-MDSCs, as compared to other myeloid cell subsets, to low dose 
gemcitabine may have different possible explanations. First, since gemcitabine activity relies on 
the inhibition of DNA replication, the greater gemcitabine cytotoxicity on M-MDSCs might be, at 
least in part, related to a higher proliferative status of these cells. Consistently with this 
hypothesis, we previously showed that spleen Gr1int and Gr1low myeloid cell subsets, mainly 
including M-MDSCs, bear an higher proliferative activity as compared with Gr1high cells (PMN-
MDSCs)21.  Besides, other possible mechanistic explanations may be envisaged.  Interestingly, 
the anti-cancer drug trabectedin was reported to selectively trigger cell apoptosis in monocytes, 
but not in granulocytes and lymphocytes53, thus displaying a cell-targeting pattern resembling 
that of low-dose gemcitabine reported in our work. The increased susceptibility to trabectedin 
of both human and mouse monocytes was shown to depend on the higher expression of TRAIL 
death receptors in these cells, which mediated the cleavage of caspase-8 and the activation of 
the extrinsic apoptotic pathway53. In addition, in a recent work by Haverkamp et al., the 
development of monocytic and granulocytic MDSC subsets was shown to be dependent on the 
continuous inhibition of  different apoptotic pathways, notably the caspase-8 dependent 
65 
 
extrinsic pathway in M-MDSCs, and the mitochondrial intrinsic pathway in PMN-MDSC44. It is 
hence possible that monocytic and granulocytic MDSCs may be intrinsically prone to cell death 
through the activation of distinct apoptotic pathways, and therefore different drugs triggering 
the same cell death pathway might cause the preferential depletion of one myeloid subset 
rather than the other.  This kind of mechanism could be hypothesized also for gemcitabine, and 
might, at least in part, explain the higher sensitivity of M-MDSCs to low drug doses. To clarify 
this hypothesis, a molecular analysis of cell death signalling pathways activated in different 
myeloid populations upon gemcitabine exposure needs to be performed, and will be subject to 
future investigations in our laboratory. 
The enhanced sensitivity to gemcitabine activity of MDSC population compared to T 
lymphocytes might have further mechanistic explanations. First, since the activation and 
proliferation of T lymphocytes in cancer is known to be restrained by multiple tumor-induced 
mechanisms (see paragraphs 1-3 in the introduction), T lymphocytes are possibly poorly 
sensitive to the gemcitabine pharmacologic action due to their low proliferation state. Indeed, 
when LNC-GemC12 was administered following the transfer of pre-activated cytotoxic 
lymphocytes (CTLs) in ACT experiments, the treatment had a negative impact on transferred 
CTLs, possibly because these cells have a high proliferative potential in the days immediately 
following the adoptive transfer.  Moreover, in a work by Vincent et al. the higher sensitivity of 
MDSCs to 5-FU with respect to other spleen immune cells (including T and B lymphocytes, NK 
cells and DCs) was mechanistically related to a lower expression of thymidylate synthase (TS), 
the enzyme inhibited by 5-FU156. TS has also been linked to gemcitabine cytotoxic activity195 and 
TS expression was shown to positively correlate with gemcitabine resistance in multiple 
pancreatic cancer cell lines, while TS inhibition increased cancer cell sensitivity to the drug196. 
Based on these observations, MDSCs’ high sensitivity to gemcitabine cytotoxicity might be, at 
least in part, related to a reduced TS expression, as previously reported for 5-FU.  
In the present work, we showed that LNC-GemC12 is a M-MDSC depleting agent more potent 
than GemHCl. The improved efficacy of LNC-GemC12 over GemHCl might be in principle due to 
the use of a modified gemcitabine molecule, covalently linked to a C12 alkyl chain (GemC12)185. 
Indeed, GemC12, as well as other lipophilic gemcitabine compounds bearing long carbon chains 
linked to the 4’ amino group, are known to improve gemcitabine stability due to drug protection 
from inactivation by cellular deaminases197.  However, when we compared M-MDSC depletion 
produced by GemHCl and by a free GemC12 solution, no substantial differences were observed.  
This result suggests that most of LNC-GemC12 enhanced efficacy relies on the lipid nanocapsule 
component. GemC12 encapsulation into LNCs might enhance drug potency by multiple 
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mechanisms, including increased drug stability, enhanced distribution to the tumor tissue and 
preferential accumulation in monocytic cells, which are singularly discussed below. 
Lipid nanocapsules (LNCs) developed by the JP. Benoit group were previously used to 
encapsulate other chemotherapeutic agents, including etoposide, paclitaxel and docetaxel, 
resulting in formulations with different sizes but always ≤ 100 nm179. Their size and the presence 
of a PEG shell make LNCs suitable to accumulate in tumors by the EPR179 effect, according to the 
criteria extensively discussed in the introduction (paragraph 4.1,4.2.). Briefly, these criteria 
include: I) a size above the glomerular filtration limit in the kidneys (8 nm) and below the 
exclusion limit for extravasation across the hyper-permeable tumor vasculature (estimated 
around 200 nm); and II) the presence of hydrophilic and neutral coating (e.g. a PEG shell), which 
reduces non-specific absorption of serum protein and prevent an excessive rate of opsonization 
and clearance by cells of the immune system, thus extending vascular residence times109. 
In addition, the more intense depletion of M-MDSCs associated to LNC-GemC12 administration 
may also depend on an increased uptake of encapsulated GemC12 as compared to free 
gemcitabine by these cells. This latter hypothesis is supported by the immune cell uptake studies 
performed with DiD-loaded LNCs, shown in figure 5. In these experiments LNCs with the same 
size and structure as LNC-GemC12, but loaded with the DiD fluorescent dye, were found to 
preferentially target M-MDSCs in the spleen and M-MDSCs and macrophages in the tumor. As 
extensively discussed in the introduction (paragraph 4.2), circulating nanoparticles bind serum 
immunoglobulins by non-specific interactions and activate complement pathways, at a variable 
extent depending on particle size, charge and composition123,124.  The reason why in our model 
monocytes/macrophages internalize LNCs more efficiently than other phagocytic cell 
populations, as DCs and granulocytic cells, is still not clear. Previous studies have already 
reported similar monocyte targeting properties of small (below 100 nm) PEGylated nanoparticle 
formulations, evaluated either in healthy mice, inflammatory disease models, or tumor 
models146,150. Based on these similarities, we could hypothesize than monocytic cells, including 
M-MDSC, are more prone to bind particle bearing physico-chemical features shared by these 
different formulations, as small size and PEGylation, with respect to other myeloid cell subsets. 
Interestingly, in a study evaluating the uptake of 100 nm albumin nanoparticles by neutrophils in 
an acute inflammation model, only activated neutrophils adhering to vessels walls, but not 
resting circulating neutrophils, were able to uptake the nanoparticles152.  Moreover, 
nanoparticle internalization by activated neutrophils was shown to  depend at least in part on 
FcγR up-regulation under inflammatory stimuli152. Based on this study, one possibility is that the 
poor LNC uptake by PMN-MDSC observed in our model might be related to a low expression of 
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FcγR and/or complement receptors by these cells that prevents an efficient binding and uptake 
of opsonized-circulating nanoparticles. However, specific studies should be performed in order 
to demonstrate this hypothesis. 
In the present work, we found that the SC administration of LNC-GemC12 was associated to a 
significantly enhanced depletion of both spleen and tumor-infiltrating M-MDSCs as compared 
with the IV administration. According to biodiostribution (BD) and pharmacokinetic (PK) studies 
on healthy mice (reported in figures 1 and 2), DiD-loaded LNCs are slowly absorbed in blood 
circulation following SC injection and reach peak accumulation in peripheral tissues, notably in 
liver and spleen, 24-48 hours following their administration. Lymph nodes near the injection site 
constitute an exception to this distribution pattern, since they are likely reached by direct 
lymphatic drainage. This in vivo behavior is typically observed for nanocarrier formulations that 
form local depots upon SC or intradermic administration, resulting in a gradual and sustained 
release of the nanocarrier and/or its cargo in the systemic circulation181,182,198. In addition, when 
we measured the distribution  of DiD-loaded LNCs in the spleen and tumor tissue sections 24 
hours following LNC injection (shown in figure 3), a significantly higher DiD signal was measured 
in mice receiving IV administration as compared to SC-treated mice, in both organs. All these 
data indicate that greater DiD concentrations are reached in spleen and tumors following IV 
injection of LNCs, as compared to SC, at least at time points ≤24 hours. However, a significantly 
enhanced M-MDSC depletion in both organs was reported in mice treated with SC LNC-GemC12. 
Based on these data, the lower maximum drug concentration reached in peripheral tissues after 
SC nanocarrier administration as compared to IV, should be equally sufficient to trigger cell 
death pathways in M-MDSCs. In addition, since gemcitabine is known to be rapidly transformed 
by cellular enzymes197, the slow but sustained LNC absorption from the SC injection site might 
continuously supply target tissue with a low drug dose, compensating its catabolic inactivation. 
In this way, the SC route might result in a lower but prolonged exposition of target tissues to the 
active drug form.   
Interestingly, a series of clinical studies compared the standard, 30-minute gemcitabine IV 
infusion versus a prolonged infusion at a low fixed-dose rate. This latter drug infusion mode was 
found to be associated with higher levels of the active gemcitabine metabolite in blood 
mononuclear cells and leukemic cells199, and with clinical benefits in pancreatic cancer 
patients200. The pharmacological  basis of this phenomenon is that slower infusion rates allow to 
keep for longer periods a drug plasmatic concentration that saturates cell enzymes involved in 
drug conversion in its active metabolite. Conversely, the standard 30 min infusion of 1000-1250 
mg/m2 results in a drug plasmatic concentration exceeding this saturation limit 199. 
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We could hypothesize that the SC administration, being associated to a gradual drug absorption 
in the systemic circulation, might mimic a prolonged infusion schedule and hence result in an 
enhanced accumulation of the drug active form in target cells, as compared with the IV 
administration of a drug bolus. This possibly applies to both LNC-GemC12 and free drug 
solutions administered SC, although drug encapsulation in nanocarriers likely results in 
enhanced sustained release, as suggest by our data. The above considerations might also explain 
why GemHCl administration by the SC route showed a slightly better efficacy as compared to 
GemHCl IV in our immunotherapy schedule (shown in figure 10). However, a specific 
pharmacokinetic analysis of GemHCl using the employed drug dose, administration routes and 
mouse model should be performed in order to test these hypothesis. 
Remarkably, in the present study we demonstrated that a very low dose (11 mg/kg) of 
encapsulated gemcitabine could be used to attenuate MDSC-induced immunosuppression and 
improve mice survival after CTL adoptive transfer. Of note, this low dose is not expected to 
cause any significant toxicity, since toxic effects in mice are usually reported only with higher  
gemcitabine doses201 or prolonged exposition to low drug doses 202. From a translational point of 
view, the present findings suggests that the use of encapsulated chemotherapeutic agents may 
allow reaching meaningful immunomulatory effects at lower drug doses than conventional 
chemotherapeutics. Specifically, LNC-GemC12 may provide better efficacy as compared to 
GemHCl, as MDSC-targeted agent.  Monocyte/macrophage-targeting proprieties of LNC-GemC12 
needs to be confirmed on human immune cells. If the unveiled targeting pattern is established, 
human cancers associated with the expansion of monocytic MDSC subsets27 might primarily 
benefit from LNC-GemC12 immunomodulatory activity.  
Gemcitabine is already being evaluated in a phase I clinal trial as MDSC-depleting agent to 
potentiate the efficacy of a DC-based vaccine (www.clinicaltrials.gov; NCT01803152). Of note, 
the population recruited in this trial is composed of advanced sarcoma patients, refractory to 
conventional therapies, in which the drug is not expected to have a substantial direct 
cytotoxicity on tumor cells and is exclusively used as immunomodulatory agent.  Data obtained 
in the present work further support gemcitabine use in combination with ACT schedules, besides 
cancer vaccines. 
Preconditioning regimens based on chemotherapy (fludarabine/cyclophosphamide) plus total 
body irradiation are currently employed to increase patient response to ACT95. These regimens 
are known to favor the expansion and function of transferred CTLs by multiple mechanisms (see 
paragraph 3.2 in the introduction), including the elimination of endogenous immunosuppressive 
cells3. The major drawback of preconditioning regimens currently employed in clinical setting, is 
69 
 
the potential of severe toxicity, which limits this therapy to highly selected patients with a good 
performance status and normal organ function100,101. The development of more effective and 
widely applicable ACT based approaches is therefore dependent on supporting treatments 
aimed at reducing tumor-associated immunosuppression with good efficacy and low toxicity.  
Although further investigation of LNC-GemC12 immunomodulatory activity in other tumor 
models is needed to consolidate the present findings, here we provide a rationale to consider 
the use of encapsulated drug formulations, instead of conventional chemotherapeutic drugs, in 
cancer immunotherapy approaches and notably in the modulation of immunosuppressive 
myeloid cells.  
In addition to its immunomodulatory activity, LNC-GemC12, administered at higher doses and/or 
for longer time periods, is also expected to have a direct anti-tumor activity and cause tumor 
regression or tumor growth delay, possibly with superior efficacy over GemHCl. This evaluation 
is currently ongoing in our laboratory.  In this setting, both MDSC depletion and direct tumor-
cytotoxiciy may contribute to control tumor progression. Moreover, the prolonged depletion of 
monocytic cells by chronic LNC-GemC12 or GemHCl administration is ultimately expected to 
cause the reduction of monocyte-derived TAMs, an effect that was not observed after a single 
LNC-GemC12 injection. It is likely that the full potential of LNC-GemC12 use in cancer therapy is 
still not fully disclosed, for both conventional cancer therapy and immunotherapy. 
In the second part of the present work, we evaluated a nanosystem platform for in vivo RNA 
delivery, which represents an additional tool to modulate selectively cancer-associated myeloid 
populations. Based on a preliminary in vitro toxicity screening  (shown in figure 11) and physico-
chemical characterization (data of MJ Alonso laboratory, not shown) of different nanocarrier 
prototypes, we selected a formulation of polyarginine-coated nanocapsules (PolyArg NCs) for 
further investigation. Besides the good toxicity and stability profile, this formulation was also 
interesting since polyarginine is a known cell-penetrating peptide, able to promote both cell 
internalization of RNA delivery systems and endosomal escape190,191. 
In order to evaluate the efficiency of this system in delivering RNA molecules and downregulate  
genes by RNAi mechanisms, we selected a relevant target gene, i.e. mouse CCAAT/enhancer 
binding protein (C/EBP)β transcription factor. C/EBPβ is known to regulate “emergency” 
granulopoyesis under inflammatory conditions, as those induced by cytokine storm or fungal 
infections, as opposed to C/EBPα, wich is instead required for steady-state but not for 
emergency granulopoiesis203. A new function for the C/EBPβ transcription factor was previously 
reported by our group, since this factor was shown to play a critical role in MDSC biology99. 
C/EBPβ expression, in fact, controlled MDSC expansion and acquisition of immunosuppressive 
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function in both in vivo tumor-induced mouse MDSCs and in vitro differentiated mouse and 
human MDSCs. Remarkably, C/EBPβ  genetic ablation in conditional knockout mice dramatically 
improved mice survival after ACT, thus supporting the relevance of C/EBPβ pathway as 
therapeutic target in cancer immunotherapy99. 
Based on these previous findings, the therapeutic silencing of C/EBPβ by RNAi might be 
employed to potentiate the efficacy of ACT.  In the present work we showed that PolyArg NCs 
loaded with a C/EBPβ-specific fluorinated shRNA significantly downregulated target gene 
expression in vitro, and we provided an initial validation of its efficacy in vivo. With the 
employed treatment schedule (20 μg RNA/mouse x 3 doses), we achieved about 50% and 30% 
reduction of C/EBPβ mRNA levels in myeloid populations (CD11b+) of the spleen and tumor, 
respectively. Such difference in C/EBPβ downregulation efficiency might reflect a stronger 
PolyArg NC accumulation in the spleen with respect to tumors and/or a stronger uptake by 
splenic myeloid populations, although specific biodistribution and uptake studies remains to be 
performed.   
The level of target gene downregulation, at least in the spleen, might be in principle biologically 
relevant, since mRNA downregulation levels around 50% have been reported to be associated 
with functional effects in the literature144,146. However, with the intent of reaching a stronger 
C/EBPβ downregualtion in the spleen and especially in the tumor, different shRNA-loaded 
PolyArg NC administration schedules, with increased RNA doses per mouse and treatment 
frequency, are currently being evaluated. 
Interestingly, in our model C/EBPβ modulation was associated with a decreased frequency of 
TAMs, paralleled by a significant increase in monocytic cells (phenotypically resembling M-
MDSCs). This pattern of altered myeloid cell frequencies is suggestive of an impaired monocyte 
differentiation into TAMs following C/EBPβ down-regulation. Our group recently reported a 
regulatory circuit controlling TAM differentiation, dependent on the microRNA miR-142-3p204. 
miR-142-3p downregulation was required for the in vitro differentiation of immunosuppressive 
macrophages and its enforced expression in the bone marrow, through the generation of mouse 
bone marrow chimeras, was associated with reduced macrophage numbers in lymphoid organs 
and tumor masses of tumor-beating hosts204. Remarkably, the regulatory activity of miR-142-3p 
involved the modulation of C/EBPβ isoform expression by direct binding of miR-142-3p to the 
C/EBPβ mRNA, resulting in a significantly reduced expression of the activating C/EBPβ isoform 
LAP*204.  This reported link between C/EBPβ modulation and tumor-induced macrophage 
differentiation  seems to support  further the hypothesis of an impaired TAM differentiation 
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following C/EBPβ silencing by shRNA-loaded PolyArgNCs. However, further experiments are 
needed to demonstrate it. 
The development of therapeutic agents able to specifically reduce the expansion of TAM pool, 
which is known to be endowed with multiple pro-tumor functions70, and/or to reduce MDSC-
mediated immunosuprression is currently object of great research efforts in the field of cancer 
immunotherapy. Our nanotechnology-based tool to modulate C/EBPβ transcription factor could 
allow reaching these kind of immunomodulatory effects, and will be therfore further 
investigated by our group. 
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Materials and methods 
 
Mice 
C57BL/6 (WT), congenic CD45.1 (Ly5+) mice and OT-I transgenic mice (C57BL/6-Tg 
(TcraTcrb)1100Mjb/Crl) were purchsed from Charles River Laboratories (Italy) and maintained 
under specific pathogen-free conditions in the animal facilities of the Istituto Oncologico Veneto 
(Padova, Italy). OT-I/CD45.1  F1 mice were obtained by crossbreeding OT-I and CD45.1 mice. 
Female C57BL/6 (WT) and female/male CD45.1 OT-I transgenic mice were used between 8 and 
12 weeks of age. For pharmacokinetic and biodistribution studies on healthy mice, female nude 
SWISS mice were purchased from Harlan (Gannat, France) and maintained at the University 
animal facility (SCAHU) in Angers (France). Experiments involving animals were performed 
according to the national guidelines and approved by the local ethics committee. 
Cell lines 
The EG7-OVA (aplotype H-2b)  lymphoma and MCA-203 (aplotype H-2b) fibrosarcoma  cell lines 
were obtained from the American Type Culture Collection and cultured in DMEM 10% FBS 
(Gibco) supplemented with 2 mM L-glutammine, 10 mM HEPES, 20 μM 2β-Mercaptoethanol, 
150 U/ml streptomycin, 200 U/ml penicillin. G418 was  added to EG7-OVA cell cultures to 
maintain transgene selection. 
The  MSC1 cell line was obtained by immortalizing tumor-induced splenic MDSCs192 and cultured 
in RPMI medium supplemented with 10% FBS Superior (Biochrom), 2 mM L-glutammine, 1 mM 
Na-pyruvate, 150 U/ml streptomycin, 200 U/ml penicillin. Cultures were maintained at 37°C with 
5% CO2. 
Nanocarriers 
LNC-GemC12 and DiD-LNCs were prepared at the laboratory of Jean Pierre Benoit (INSERM – 
U1066 Institut de Biologie en Santé (IBS)-Centre Hospitalier Universitaire (CHU), Angers ,France). 
LNC-GemC12 and DiD-LNCs synthesis procedure is described in Moysan et al., Soft matter. 
2014185 and in Bastiat et al., J Control Release. 2013180.  
HA-nanocapsules, HA-protamine nanocapsules (PEG-st), HA-protamine nanocapsules (succinate 
and sodium cholate) and polyarginine nanocapsules (PolyArg NCs) were prepared in the 
laboratory of Maria Josè Alonso at the Center for Research in Molecular Medicine and Chronic 
Diseases (CIMUS), Santiago de Compostela, Spain.  
All formulations were stored at +4°C , except for shRNA-loaded PolyArg NCs, which were freeze-
dried soon after RNA loading and stored at -20°C. 
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Preparation of cell suspensions from tumors and lymphoid organs 
Mice were euthanized and spleens, tumors and axillary and inguinal lymph nodes were 
collected. Tumors were cut in small pieces and incubated with a digestive solution composed of 
collagenase IV (1 mg/ml), hyaluronidase (0.1 mg/ml), DNase (0.03 KU/ml) 37°C for 1 hour; every 
10 minutes, tumors were mechanically disaggregated using a 5 ml pipette.  At the end of 
digestion, tumor cells were collected, filtered to remove cell clumps and debris and washed in 
complete medium twice to remove all digestive solutions prior to subsequent use. 
Spleens and lymph nodes were mechanically disaggregated and filtered with 100 μm filters.  
Cytofluorimetric analysis  
Red blood cells were removed from cell suspension using a hypotonic lysis solution and cells 
were washed with cold PBS and incubated 10 min at +4°C with purified anti-FcγR  antibody 
(clone 2.4G2) to minimize non-specific antibody binding. Antibodies of interest were  added to 
cell suspensions following FcγR blocking and incubated 20 min at +4°C in the dark. 
Employed antibodies were: anti-CD11b PE-Cy7 (clone M1/70), anti-CD11b PerCP-Cy5.5 (clone 
M1/70),  anti-LY6G APC-Cy7 (clone 1A8), anti-CD11c BV421 (clone HL3), anti CD115 PE (clone 
AFS98) anti-I-A/I-E PerCP-Cy5.5 (clone M5/114.15.2), anti-LY6C eFluor 450 (clone HK1.4), anti-
CD4 APC (clone RM4-5), anti-CD45.1PE (clone A20), anti-CD8 PerCP-Cy5.5 (clone 53-6.7), anti-
CD3 FITC (clone 145-2C11)(all from eBioscience), anti-F4/80 FITC (AbDSerotec, clone CI:A3-1). 
Aqua LIVE/DEAD® dye (Invitogen) was used to analyze cell viability. 
For intracellular staining of INF-γ the BD Citofix/Cytoperm Kit was used, according to 
manufacturer’s instruction. INF-γ was stained using anti-INF-γ FITC (clone XMG1.2, BD)  
Flow data were acquired with a  BD LSRII  or BD FACS Calibur instrument and analyzed with 
FlowJo (Tree Star, Inc.) software 
Ex vivo T cell suppression assay 
CD11b+ cells were isolated from tumors with anti-CD11b MicroBeads (Miltenyi Biotec, Germany).  
OT-I/CD45.1 splenocytes derived from the spleen of OT-I mice were labeled with 
carboxyfluorescein succinimidyl ester (CFSE, CFSE-Cell Trace Kit, Invitrogen Molecular Probe) 
according to manufacturer’s instructions. A mixed leucocyte peptide culture (MLPC) was 
prepared by mixing -irradiated C57BL/6 splenocytes with OT-I/CD45.1 CFSE-labeled splenocytes 
in order to obtain 1% OT-I T CD8+ lymphocytes in the final culture. MPLC culture was plated in 
flat-bottom 96-well plates (0.6x106 cells/well) and 1 μg/ml H-2 Kb-restricted OVA peptide 
(OVA257-264, SIINFEKL, synthesized by JPT, Peptide Technologies, Germany) was added to the 
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culture to stimulate OVA-specific OT-I T CD8+ lymphocytes. CD11b+ cells were added at 
degreasing percentages with respect to MLPC culture(24%, 12%, 6%, 3% and 1,5%). Cultures 
were maintained at 37°C with 5% CO2 in RPMI medium supplemented with 10% FBS Superior 
(Biochrom), 2 mM L-glutammine, 1 mM Na-pyruvate, 150 U/ml streptomycin, 200 U/ml 
penicillin, 20 μM 2β-mercaptohetanol. 
After 3 days of culture cells were collected, washed with cold PBS and stained with anti-CD45.1 
PE (clone A20, eBioscience) and anti-CD8 PerCP-Cy5.5 (clone 53-6.7, e Bioscience). Flow data 
were acquired with a FACSCalibur flow cytometer (BD Biosciences) and analyzed with FlowJo 
(Tree Star, Inc.) software. The percentage of cells in 0 to 7 generation of proliferation was 
determined based on CFSE dilution within the CD8+CD45.1+ gate. 
Fluorescent immunohistochemistry (IHC) 
Tumor and spleen samples were fixed in 4% Paraformaldehyde (PFA), de-hydrated through 
sequential passages in 20% and 30% sucrose solutions and frozen in a cryo-embedding medium 
(OCT, Bio-Optica, Milan, Italy). 7 μm tissue sections were prepared and stored at -20°C until 
usage. For IHC staining, tissue section were re-hydrated in PBS, fixed  in 4% PFA for 5 minutes at 
room temperature (RT), incubated 1h RT with a blocking solution (PBS 10% FBS) to reduce non-
specific binding, and stained overnight with rat anti-mouse CD11b-FITC (clone M1/70 
eBioscience). Goat anti-rat IgG Alexa Fluor 488 (Abcam) was used as secondary antibody and 
incubated 3 hours at RT. Nuclear staining was performed with DAPI (Invitrogen) for 10 minutes 
at RT. Slices were mounted with ProLongR Gold Antifade Reagent (Invitrogen). Images were 
acquired with a Zeiss LSM 510 confocal microscope. MFI in the DiD channel was measured on 4-
7 randomly selected fields per tissue section, and means MFI ± standard errors (SE) were 
calculated for tissue sections from n=3 mice per group. 
MDSC generation from bone marrow cells 
Bone marrow cells were isolated from tibiae and femurs of C57BL/6 mice  and red blood cells 
were lysed with hypotonic solution.  1,5x106 bone marrow cells/well  were plated in  6-well 
tissue culture  plates (Falcon,Corning) in 2 ml of RPMI  medium supplemented  with 10% FBS 
Superior (Biochrom), 2 mM L-glutammine, 1 mM Na-pyruvate, 150 U/ml streptomycin, 200 U/ml 
penicillin, 20 μM 2β-mercaptohetanol. Recombinant murine GM-CSF and IL-6  (Peprotech) were 
added at 40 ng/ml final concentration to induce differentiation of bone-marrow derived MDSCs 
(BM-MDSCs), as previously reported99. Cultures were incubated for 4 days at 37°C with 5% CO2. 
Cells from the non-adherent and adherent fraction were collected by rinsing the dishes with PBS 
2mM EDTA and used for flow cytometry analysis. 
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In vivo treatments on tumor bearing mice 
To establish tumors, EG7-OVA cells (0.5x106 cells/mouse) or MCA203 cells (1x106 cells/mouse) 
were injected subcutaneously (SC.) on the left flank  of C57BL/6 mice, and tumor growth was 
monitored every 2 days by digital calipers.  
LNC-GemC12, Gemcitabine hydrochloride and free GemC12 were administered either SC, on the 
right flank ,or intravenously (IV), on the tail vein. All treatments were administered at a 11 mg/kg 
Gemcitabine or GemC12 dose. For tracking of DiD-loaded LNCs (DiD-LNCs) by fluorescence 
microscopy on tissue section and by flow cytometry,  mice were injected with 8.8 mg of DiD-
LNCs (≈4 μg of DiD dye), corresponding to the same amount of LNC per mouse administered in 
experiments with LNC-GemC12. In the EG7-OVA model, treatments were administered after 8 
days following EG7-OVA cell injection (tumor surface approximately 50 mm2). 
In experiments with shRNA-loaded polyarginine nanocarriers (PolyArg NCs), treatments were 
started at day 11 from MCA203 tumor cell injection, when tumor surfaces were approximately 
35 mm2, and repeated 3 times with 48 hours intervals (RNA dose= 20 μg/mouse/treatment).  
Adoptive  T cell therapy (ACT) 
ACT was administered to mice bearing EG7-OVA tumors, after 9 days from tumor cell injection. 
OVA specific CD8+CD45.1+  cytotoxic T lymphocytes  (CTLs) were prepared  by culturing  OT-
I/CD45.1 splenocytes  in presence of 1 μg/ml OVA257-264 (SIINFEKL) peptide and  20 IU/ml IL-2 
(Novartis, Basel, Switzerland). Cell cultures were maintained 7 days before in vivo injection.  
OVA-specific CTLs were injected IV on the tail vein (0.25x106  cells/mouse).  
Pharmacokinetic and biodistribution of DiD-loaded LNCs (DiD-LNCs) in healthy mice 
Pharmacokinetic and biodistribution experiments in healthy mice were performed in the in the 
laboratory of Jean Pierre Benoit (INSERM – U1066 Institut de Biologie en Santé (IBS)-Centre 
Hospitalier Universitaire (CHU), Angers ,France). 
Healthy female nude SWISS mice  of 9 weeks of age were injected with DiD-LNCs  either 
subcutaneously (sc) behind the neck, or intravenously (iv) into the tail vein.  Each mouse was 
injected with 48 mg DiD-LNCs, corresponding to 24 μg of DiD dye. At sequential time points from 
DiD-LNC injection  (1h, 4h, 8h, 24h, 48h,  96h and 336h ) mice were sacrificed, blood was 
collected by cardiac puncture  and organs were removed for biodistribution analysis . Plasma 
from each blood sample was obtained after 10 min of centrifugation at 2,000 g.  DiD 
concentrations in plasma (encapsulated inside LNC) along time were determined using a 
microplate reader Fluoroscan Ascent® (Labsystems SA, Cergy-Pontoise, France) at excitation and 
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emission wavelengths of 646 and 678 nm, respectively. DiD concentrations in plasma were 
intrapolated from linear curve between 0.006 and 12 µg/mL (r2 > 0.999). Pharmacokinetic data 
were determined by iv bolus and extravascular non-compartmental analysis (for iv and sc 
administration, respectively) of the recovered systemic DiD concentration versus time using 
Kinetica 4.1.1 software (Thermo Fisher Scientific, Villebon sur Yvette, France). The trapezoidal 
calculation method was used to determine the area under the curve (AUC) during the whole 
experimental period (from 1 to 336 h) without extrapolation. The t1/2 were calculated from 1 to 8 
h for t1/2 distribution and from 8 to 336 h for t1/2 elimination.  
For the biodistribution study, the organs (i.e., kidneys, liver, spleen, lung, heart, stomach, and 
intestine), and lymph nodes (i.e., inguinal, axillary, cervical and brachial lymph nodes) were 
removed and analyzed by a fluorescence CRI MaestroTM imaging system (Woburn, USA). Semi-
quantitative data were obtained by setting a time exposition of 10 ms between 630 and 800 nm, 
unmixing the generated cube, extracting the background and drawing the regions of interest 
from fluorescence images (Figure 1-A). The software Maestro 2.10 (Woburn, USA) was used to 
calculate the average signal expressed in photon/cm²/s. 
Cell transfection 
5*104  MSC1 cells/well were plated  in 24-well plates (Falcon, Corning) the day before 
transfection. 
Nacked shRNAs were transfected using the Lipofectamine RNAi Max®  reagent (Invitrogen) 
according to manifacturer’s instruction. Freeze-dryed  shRNA-loaded PolyArg NCs were 
reconstituted  in RNase free water and added to the cell culture. Cells were harvested 24 hours 
after transfection. 
RNA extraction and qRT-PCR 
CD11b+ cells were isolated from tumors ant spleens with anti-CD11b MicroBeads 
(MiltenyiBiotec, Germany) and total RNA was extracted using  the miRNeasy Micro Kit (Qiagen) 
according to manifacturers’ instructions. For in vitro experiments, TRIzol® reagent (Invitrogen) 
was added directly to the culture plate after medium removal, and   total RNA was extracted 
according to the TRIzol® extraction protocol. Following TRIzol® extraction, genomic DNA 
contaminants were removed using the TURBO DNA-free™ Kit (Ambion). 
cDNA was generated using the reverse transcriptase SuperScript II and polydT12-18 primers 
(Invitrogen).  PCR and fluorescence detection were performed using the ABI 7900HT fast real-
time PCR Systems in a reaction volume of 20 μl containing 1× TaqMan Universal PCR Master Mix 
(Applied Biosystems) and 50 ng cDNA. For quantification of mouse Cebpb and Rn18s the 1× 
TaqMan Gene Expression Assays Mm00843434_s1 and Mm03928990_g1 (Applied Biosystems) 
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were used. All measurements were performed in duplicates and were analyzed by the ΔΔCt 
relative quantification method: the arithmetic means of the cycle threshold (Ct) values were 
calculated and target gene mean Ct values were normalized to the respective endogenous 
control (Rn18s), and then to ΔCt value of control samples. The values obtained were 
exponentiated 2(−ΔΔCt) to be expressed as n-fold changes in regulation compared with the 
reference sample. 
Synthesis of fluorinated short hairpin (sh) RNAs 
Specifically designed, self-annealing ssDNA primers were purchased from Eurofins MWG Operon 
and were used to obtain dsDNA  by PCR extension. PCR extension was performed in a 50 μl final 
reaction volume containing 1x PCR buffer, 2,5 mM MgCl2 , 0.2 mM dNTPs, 1 U Taq DNA 
polymerase (all from Invitrogen) and 20 μM ssDNA primers. A single PCR cycle was run with the 
following protocol: 95°C 10min,  60°C 1 min, 72°C 20min.  dsDNA was purified using the Wizard® 
SV Gel and PCR Clean-up system (Promega) according to manufacturer’s instruction. 
1 ug of dsDNA was used as template to transcribe shRNA molecules  in a single in vitro 
transcription (IVT) reaction, using the DuraScribe® T7 transcription kit (Epicentre).  IVT reaction 
was run overnight at 37°C in a temperature-controlled oven. DNA template was removed by 
DNase I digestion and shRNAs were purified using the miRNeasy Micro Kit (Qiagen). Purified 
shRNAs were quantified by spectrophotometer and correct molecule length was checked by 
denaturing gel electrophoresis (polyacrilammide 15%, urea 7M). 
Purified shRNAs were used for cell transfection experiments or shipped to the Center for 
Research in Molecular Medicine and Chronic Diseases (CIMUS), Santiago de Compostela, Spain 
for loading on PolyArg NCs. The workflow for fluorinated shRNA synthesis is graphically 
represented in figure 12 in the result section. ssDNA Primer sequences for the generation of the 
C/EBPβ-specific shRNA and control scrambled shRNA were kindly provided by Paolo Serafini 
(University of Miami, Department of Microbiology and Immunology, University of Miami, Miami, 
Florida, USA). 
Statistical analysis 
Values are reported as means ± standard errors (SE). Survival experiments are reported as 
Kaplan-Meyer curves and significance was determined with log-rank test with p-value correction 
for pairwise multiple comparisons by the Holm-Sidak method. Student’s t-test was performed on 
groups with normal distribution, as evaluated by Shapiro-Wilk normality test. For non-normal 
data, group comparison was performed using the Mann-Whitney Rank Sum Test.  Values were 
considered significantly with p≤0.05 and are indicated as *p≤0.05; **p≤0.01 and ***p≤0.001. 
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Abbreviations 
 
5-FU……………………………………………………………………………………………………………………...5-Fluorouracile 
ACT ................................................................................................................. Adoptive cell therapy  
APC ...............................................................................................................Antigen presenting cell  
APC ......................................................................................................................... Allophycocyanin  
ARG .................................................................................................................................. Arginase  
ATRA .............................................................................................................. All-trans retinoic acid  
BM ............................................................................................................................. Bone Marrow  
C/EBP ......................................................................................... CCAAT-enhancer-binding protein  
CCR2……………………………………………………………………………………C-C chemokine receptor type 2 
CD ............................................................................................................. Cluster of differentiation  
CSFE .....................................................................Carboxyfluorescein diacetate succinimidyl ester  
CTL ............................................................................................................ Cytotoxic T lymphocyte  
CTLA4 ....................................................................................... Cytotoxic T-Lymphocyte Antigen 4  
DNA…………………………………………………………………………………………………………….Deoxyribonucleic acid 
DAPI ................................................................................................ 4',6-diamidino-2-phenylindole  
DC ................................................................................................................................ Dendritic cell  
DMEM ...................................................................................... Dulbecco's Modified Eagle Medium  
EDTA ............................................................................................. Ethylenediaminetetraacetic acid  
EGF............................................................................................................ Epidermal growth factor  
EPR……………………………………………………………………………………. Enhanced permeability and retention  
FBS .................................................................................................................... Fetal bovine serum 
FSC……………………………………………………………………………………………………………………….Forward scatter  
FITC ....................................................................................................... Fluorescein isothiocyanate  
Foxp3 .................................................................................................................... Forkhead box P3   
G-CSF .................................................................................. Granulocyte colony-stimulating factor  
GemC12……………………………………………………………………………………………………………..Gemcitabine C12 
GemHCl……………………………………………………………………………………………… Gemcitabine hydrocloride 
GM-CSF ..........................................................Granulocyte-macrophage colony-stimulating factor  
HEPES ........................................................... 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HIF........................................................................................................... Hypoxia-inducible factors  
HLA ......................................................................................................... Human leukocyte antigen 
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IP…............................................................................................................................ Intraperitoneal  
IDO .....................................................................................................Indoleamine 2,3-dioxygenase  
IL ................................................................................................................................... Interleukin  
INF ................................................................................................................................. Interferon  
iNOS ................................................................................................ Inducible Nitric  oxide synthase  
IV………………………………………………………………………………………………………………………………..Intravenous 
IVT…………………………………………………………………………………………………................In vitro transcription 
JAK ............................................................................................................................... Janus kinase  
KO ....................................................................................................................................Knock-Out  
LNC……………………………………………………………………………………………………………………Lipid nanocapsule 
LPS ..................................................................................................................... Lipopolysaccharide  
MCA ................................................................................................................ Methylcholanthrene  
M-CSF ................................................................................. Macrophage colony-stimulating factor  
MDSC ............................................................................................ Myeloid derived suppressor cell 
miRNA……………………………………………………………………………………………………………………………microRNA  
MHC ........................................................................................... Major histocompatibility complex  
MLPC ....................................................................................... Mixed lymphocyte-peptide culture  
M-MDSC ..................................................................... Monocytic-Myeloid derived suppressor cell  
MMP ....................................................................................................... Matrix metalloproteinase  
MR…………………………………………………………………………………………………………………..Mannose Receptor 
NC……………………………………………………………………………………………………………………………..Nanocapsule 
NF-κB ............................................ Nuclear factor kappa-light-chain-enhancer of activated B cells  
NK ......................................................................................................................... Natural killer cell  
OCT ................................................................................. Optimal cutting temperature compound  
OVA ................................................................................................................................. Ovalbumin  
PBS ......................................................................................................... Phosphate buffered saline 
PD-1………………………………………………………………………………………… Programmed cell death protein 1  
PD-L1…………………………………………………………………………    Programmed cell death protein ligand 1  
PDE5 ............................................................................................................... Phosphodiesterase 5  
PE ............................................................................................................................... Phycoerythrin 
PEG…………………………………………………………………………………………………………………Polyethylene glycol  
PerCPCy5.5 .......................................................... Peridinin-chlorophyll-protein complex cyanin5.5  
PMN-MDSC ....................................................Polymorphonuclear myeloid derived suppressor cell  
PolyArg………………………………………………………………………………………………………………………Polyarginine 
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qRT-PCR……………………………………………………………………...Quantitative reverse transcriptase PCR 
RNA……………………………………………………………………………………………………………………..Ribonucleic acid 
RNAi…………………………………………………………………………………………………………………..RNA interference 
RNS ......................................................................................................... Reactive nitrogen species  
ROS ...........................................................................................................Reactive Oxygen Species  
RT ...................................................................................................................... Room temperature  
SC............................................................................................................................... Subcutaneous  
SCF ........................................................................................................................... Stem cell factor  
SD……………………………………………………………………………………………………………………Standard deviation 
siRNA…………………………………………………………………………………………………………..Small interfering RNA 
shRNA…………………………………………………………………………………………………………….. Short hairpin RNA 
SSC………………………………………………………………………………………………………………................Side scatter 
STAT..................................................................... Signal transducer and activator of transcription  
TAM ................................................................................................ Tumor associated macrophage  
TCR ........................................................................................................................... T cell receptor  
TGF ................................................................................................................. Tumor growth factor  
Th....................................................................................................................................…….T helper  
TIL .................................................................................................... Tumor infiltrating lymphocyte  
TLR ........................................................................................................................ Toll-like receptor  
TNF ............................................................................................................... Tumor necrosis factor  
Treg .......................................................................................................... T regulatory lymphocyte  
VEGF ........................................................................................ Vascular endothelial growth factor  
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